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 Klebsiella pneumoniae causes an acute respiratory infection in human 
with severe outcomes and high mortality rates even with antibiotic treatment. 
Even with its critical clinical importance, few virulence systems have been 
identified for K. pneumoniae limiting the development of new therapeutic 
strategies. Accordingly, we performed Next Generation sequencing for the strain 
ATCC 43816, a virulent strain in mouse respiratory disease models, and 
compared its genomic data with two previously sequenced strains NTUH-K2044 
and MGH 78578 for the purpose of identifying genes required for colonizing host 
lungs. Furthermore, the virulence potential of the three K. pneumoniae strains 
were tested in a mouse model of pulmonary disease uniquely generated by our 
group to insure the specific delivery of an inoculum into host lungs allowing for 
studying diseases associated specifically with the lower respiratory tract. To 
monitor disease progression noninvasively, a bioluminescent K. pneumoniae 
strain was engineered which allowed for monitoring meropenem therapeutic 
efficacy against the bacteria in real time. A transposon mutant library was 
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generated in the bioluminescent strain and introduced into mice lungs in order 
identify critical fitness factors required by K. pneumoniae to survive the selective 
pressure of host lung. The attenuation of known and potential virulence factors, 
including capsular polysaccharide (CPS) and type 6 secretion systems (T6SSs), 
were tested in our lung-specific murine model of respiratory disease. Similar to 
previous findings, manC capsule mutant was attenuated in our lung-specific 
disease model whereas for the vgrG T6SSs mutants, only cluster one illustrated 
some potential attenuation in the host, and future studies will be conducted to 
confirm these outcomes. K. pneumoniae is thought to be an extracellular 
pathogen but we have provided the first evidence suggesting that this dogma 
might not be entirely true by demonstrating the capability of the bacteria to 
proliferate within cultured macrophages in addition to the ability of a 
subpopulation of K. pneumoniae to become intracellular within mice lungs. 
Further studies will need to be conducted to identify the role(s) of the intracellular 
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The Klebsiella genus was named after the German microbiologist Edwin 
Klebs whom due to his efforts in combination with other researchers we came to 
understand the ability of this bacteria in causing acute respiratory infections in 
humans [1-3]. The first isolation of bacteria from the Klebsiella species was from 
patients with rhinoscleroma, a chronic granulomatous disease of the upper 
respiratory tract [4], which was named by Trevisan at 1887 as Klebsiella 
rhinoscleromatis. At 1893, Abel observed capsulated rod-shaped organisms in 
nasal secretion of patients with ozaena, and therefore, he named that bacteria as 
Bacillus mucosus ozaenae which was later transferred into the Klebsiella genus 
as Klebsiella ozaenae [5].  
Among the Klebsiella genus, Klebsiella pneumoniae is the most clinically 
significant species which is also known as Friedländer’s bacillus due to the effort 
done by his group where Hans Christian Gram developed the Gram staining that 
enabled distinguishing Klebsiella pneumoniae from Streptococcus pneumoniae 
as causative agents for respiratory disease in humans [3, 6]. Initially, Klebsiella 
rhinoscleromatis and Klebsiella ozaenae were recognized as distinct species, but 
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due to their indistinguishable DNA relatedness to Klebsiella pneumoniae [7], they 
are now considered as a subspecies of Klebsiella pneumoniae according to 
Ørskov’s Bergey’s Manual of Systematic Bacteriology [8]. For the purpose of this 
dissertation Klebsiella pneumoniae subspecies pneumoniae will be referred to as 
K. pneumoniae. 
 
1.2  Epidemiology  
Klebsiella species are ubiquitous in the environment in which they are 
found in soil, sewage, surface water, and on plants [9-13]. They are also good 
colonizers of mammalian mucosal surfaces where they colonize human, swine, 
and equine [14]. K. pneumoniae is a saprophyte in human’s nasopharynx and 
gastrointestinal (GI) tract where the asymptomatic carriage rate of the bacteria 
varies from 1 – 6% in the nasopharynx, with increased carrier rate with 
alcoholism, and from 5 – 38% in stool samples [14, 15]. Klebsiella spp. is rarely 
found on the skin where it is considered to be a transient flora [16].  
In the hospital setting, the carrier rate of Klebsiella increases significantly 
in patients as well as in health care personnel [17-19]. The carrier rate of the 
bacteria in patients is proportionally related to length of hospitalization and the 
excessive use of antibiotics, especially those with broad-spectrum effect [20, 21]. 
Patients with hospital-acquired intestinal Klebsiella have four-fold higher rate of 
Klebsiella nosocomial infections than non-carriers [22]. With such knowledge in 
mind, prescription and administration of antibiotics must be wisely controlled by 
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health care providers in addition to the application of high hygienic practices to 
prevent the spread of the bacteria in the hospital.  
The main mode of transmission of Klebsiella in the hospital is through the 
fecal-oral route and the contaminated hands of the health care providers [23]. 
The rapid spread capability of the bacteria lead to outbreaks in the hospital 
setting especially in the neonatal wards [24, 25]. Klebsiella have caused 13 
epidemic hospital-acquired infections out of 145 epidemics between 1983 and 
1991 [14, 26]; bacteria from this species is responsible for 8% of endemic 
nosocomial infections and 3% of epidemic outbreaks according to the CDC [27]. 
The ability of Klebsiella to cause outbreaks in the hospital in addition to the 
increase in the multidrug resistant (MDR) isolates makes this bacterium a public 
threat to human health.   
 
1.3  Clinical Significance 
K. pneumoniae is mainly a nosocomial pathogen where it causes urinary 
tract infections, septicemia, wound infections, intestinal infections, and 
pneumonia in susceptible individuals [14]. People at risk of acquiring K. 
pneumoniae infection include immunocompromised individuals such as neonates 
and the elderly [14]. People with underlying diseases or undergoing treatments 
that impair their immune defenses are also predisposed to K. pneumoniae 
infections. This include patients with chronic obstructive pulmonary disease 
(COPD), diabetes mellitus, hepatobiliary disease, malignancies, renal failure, 
alcoholism, and those undergoing glucocorticoid therapy [28-38]. Among the 
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other infections, the respiratory disease caused by K. pneumoniae is very severe 
and is associated with high mortality rates even with antibiotic administration [14]. 
 
1.3.1 K. pneumoniae respiratory infections 
1.3.1.1 Hospital-acquired pneumonia 
K. pneumoniae is a common causative agent for respiratory disease in the 
hospital in which it is responsible for 8.4% of ventilator-associated pneumonia 
(VAP), 7.1% of hospital-acquired pneumonia (HAP), and 7.6% of non-nosocomial 
healthcare-associated pneumonia (HCAP), which involves infections that take 
place in long-term care facilities [39]. The clinical picture of HAP or VAP by K. 
pneumoniae involves pulmonary infiltrate, fever, cough with increased sputum 
production, and leukocytosis [40, 41]. Upper respiratory tract bacterial 
colonization in hospitalized patients is common, especially in those who require 
ventilator support or patients that need to be admitted into the ICU [41].  K. 
pneumoniae HAP often present as bronchitis or bronchopneumonia and the most 
frequent computed tomography (CT) scan observations include ground glass 
opacities, alveolar consolidation, intralobar reticular opacities, and pleural 
effusions [42].    
 
1.3.1.2 Community-acquired pneumonia 
K. pneumoniae is an uncommon causative agent for community-acquired 
pneumonia (CAP) in the USA, Europe, Argentina, and Australia where it mostly 
affect diabetic, alcoholic patients, or individuals with severe COPD [28, 43]. 
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However, more cases of K. pneumoniae CAP have been reported in Taiwan and 
South Africa, which might be due to differences in socioeconomic factors such as 
primary healthcare and environmental sanitation, bacterial strains, or host 
defense [28, 44]. Another possibility includes differences in characterizing the 
respiratory disease caused by K. pneumoniae as CAP since in some studies 
HCAP cases are included as part of the CAP [45]. HCAP includes hospitalization 
for a couple of days during the preceding three months, residence in nursing 
home or extended care facility, home wound care, chronic dialysis during the 
past month, and home infusion therapy [45]. Thus, the cases that are being 
reported as K. pneumoniae CAP in such studies could actually be acquired from 
healthcare settings rather than from the community. Although K. pneumoniae is 
not a frequent causative agent for CAP, this bacterium accounts for a higher 
fraction of isolates associated with more critical infections [39, 46-48].  
The clinical manifestation of CAP by K. pneumoniae resemble the 
pneumonic disease acquired from the hospital setting, which include fever, 
coughing, increased sputum secretion, pleuritic chest pain, tachypnea, dyspnea, 
crackles during the physical examination, and leukocytosis [41]. Furthermore, K. 
pneumoniae CAP is also accompanied with significant inflammation and necrosis 
that progress into thick, mucoid, and blood-tinged sputum which is alluded to as 
“currant jelly” sputum [41]. Unlike to the radiographic observations in K. 
pneumoniae HAP, the community-acquired disease frequently generate a lobar 
respiratory infection similar to the radiological picture of pneumonia caused by 
Streptococcus pneumoniae  [42, 49]; therefore, the radiographic findings alone 
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are not enough to identify Klebsiella as the causative agent for the pulmonary 
disease. 
Mortality rates of K. pneumoniae CAP are quite high, even with the early 
administration of proper antibiotic regimen, especially if the bacteria 
disseminated to the bloodstream causing bacteremia [41, 50]. In patients with 
lobar pneumonia, respiratory failure is the most common cause of death, 
especially when the bacteria disseminate rapidly, leading to multi-lobar 
involvement or if the pneumonic disease progressed into an acute stage [41]. 
Therefore, the rapid administration of the proper antibiotic therapy is of a great 
importance for preventing the development of a lethal incurable infection.     
 
1.4 Treatment  
The empiric treatment for patients with severe K. pneumoniae respiratory 
infection include antibiotics effective against Gram-negative bacteria (GNB), 
aggressive ventilation, and clinical and radiographic monitoring for entities 
treatable through surgical intervention such as lung abscess, pulmonary 
gangrene, and empyema [51-53]. Most K. pneumoniae respiratory infections are 
treatable by third generation cephalosporin or quinolones, while macrolides 
antibiotics are not effective against this bacteria [54]. Even though the 
advantageous activity of combination therapy is debatable [51, 55-57], it is still 
being used for treating Klebsiella respiratory infections, and the recommendation 
is to use beta-lactam in addition to an aminoglycoside antibiotic to which the 
bacteria is susceptible instead of using two beta-lactam agents [54].  
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When treating a respiratory infection cause by GNB using aminoglycoside, 
it is critical to dose the antibiotic aggressively aiming to achieve a peak 
concentration/minimum inhibitory concentration ratio of 10 or more during the 
initial 48 hours so that maximum outcomes might be attainted [58]. In addition to 
the systemic administration of aminoglycosides to treat lung infection caused by 
GNB, endotracheal delivery of the antibiotics were utilized but even though this 
type of therapeutic was able to eliminate pathogens from sputum more 
frequently, it had no significant impact on clinical outcome [59].  
While treating a bacterial infection, it is critical to administer the 
antimicrobial agents for the appropriate duration in order to prevent disease 
relapse and to avoid generating drug resistant isolates. The recommended 
minimum duration to treat K. pneumoniae respiratory infection is 10 days, which 
should be coupled with the performance of CT scan on patient chest, in order to 
remove entities that need to be treated through drainage or debridement such as 
in the case of abscess formation or empyema [53]. Last, it has been 
demonstrated in most cases that it is safe to switch therapy into oral 
administration of quinolone to which the bacteria is susceptible if a quick 
improvement to the intravenous treatment was observed [60, 61].   
 
1.5  Multi-drug Resistance 
The trend of the increasing resistance to a wide range of antibiotics is 
alarming for K. pneumoniae clinical isolates. The ability of the bacteria to 
generate extended-spectrum beta-lactamases or carbapenemases should be 
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taken into consideration when initiating therapeutic regimen against K. 
pneumoniae infections.  
 
1.5.1 Extended-Spectrum Beta-Lactamases  
The Extended-Spectrum Beta-Lactamase (ESBL) producing 
microorganisms confer resistance to most beta-lactam antimicrobial agents, 
including monobactam, penicillin, and cephalosporin limiting the treatment 
options [41]. Outbreaks of ESBL-producing K. pneumoniae isolates have been 
described around the globe [30, 62-66]. Among a multi-country 455 consecutive 
episodes of hospital-acquired K. pneumoniae bacteremia in the period from 1996 
to 1997, the ESBL-producing isolates accounted for 31% of all cases and 44% of 
the episodes that were acquired in the ICU [62]. The ESBL-producing strains 
identified within the same healthcare facility had similar genotype patterns 
indicating patient-to-patient transmission [62]. Infections by ESBL-producing K. 
pneumoniae strains are associated with increased mortality rates, and therefore, 
safety measures should be taken to avoid the spread of such isolates within the 
hospital [67]. Patients receiving multiple drugs or broad-spectrum antibiotics are 
at higher risk for developing MDR Klebsiella strains that are not limited to ESBLs, 
emphasizing the importance of the proper antimicrobial administration [30, 62, 
66, 68].  
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1.5.2 Carbapenem Resistance  
Carbapenem-hydrolyzing beta-lactamases K. pneumoniae strains have 
been isolated worldwide [41]. K. pneumoniae is the most frequent bacteria to 
carry carbapenemase (KPC) and New Delhi metallo-beta-lactamase (NDM-1) 
enzymes that break all beta-lactams reducing the therapeutic efficacy of 
carbapenems and beta-lactamase inhibitors [41]. Prior administration of broad-
spectrum carbapenem and/or cephalosporin is a major risk for the development 
of KPC and NDM-1 strains but not essentially required [69-71]. The mortality rate 
associated with KPC infection can get as high as 50%; thus, upon the 
identification of a positive KPC case, infection prevention control precautions 
should be followed more carefully (e.g. wearing proper protective clothing and 
hand hygiene practices) to avoid spreading the pathogen [72]. 
In addition to the reduced susceptibility to beta-lactam and carbapenems, 
the carbapenemase-producing strains often encode for genes that make them 
resistant to other antibiotics including fluoroquinolones and aminoglycosides [73, 
74]. For KPC, the resistance rate to fluoroquinolones is 98%, and ~50% to 
amikacin and gentamicin [75]. Resistance to carbapenem can also take place by 
the loss of the outer membrane porins including OmpK35 and OmpK36 coupled 
with the presence of the extended-spectrum and/or AmpC beta-lactamases [76, 
77]. Furthermore, the use of the carbapenem antibiotics might select for KPC 
strains generated by porin loss [78]. Collectively, the therapeutic options for KPC 
are limited and the choice of antibiotic should take into account the outcomes of 
antimicrobial susceptibility testing.  
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1.6 Treatment of MDR Klebsiella 
1.6.1 Treatment of ESBL-producing Klebsiella 
ESBL-producing microbes are associated more frequently with 
nosocomial infections rather than the community acquired ones [54]. Risk factors 
associated with acquiring ESBL-producing Klebsiella infection include previous 
infection with such isolate, ICU hospitalization, or other wards accommodation 
that are known to contain endemic ESBL-producing organisms, and if the patient 
has a recent history of third generation cephalosporin administration [54]. The 
most effective treatment for the ESBL-producing isolates is the carbapenem 
drugs [79-81]. 
 Imipenem and meropenem antimicrobial agents of the carbapenem family 
are the drugs of choice for treating ESBL-producing bacteria [79]. Although there 
is some in vitro data supporting the use of carbapenem and aminoglycoside 
combination therapy, such as the use of carbapenem with amikacin to treat 
severely ill patients, there is no clinical evidence that illustrate a clear advantage 
of such treatment over monotherapy [54]. Furthermore, quinolones are being 
used as a second-line treatment for K. pneumoniae infections caused by ESBL-
producing isolates even though there is a higher possibility for the development 
of resistance to these antibiotics by ESBL-producing bacterial isolates than those 
that are not [79, 82].  
The combination of beta-lactam/beta-lactamase inhibitor such as 
ticarcillin/clavulanate or piperacillin/tazobactam might be effective against ESBL-
producing K. pneumoniae but they are subjected to higher minimum inhibitory 
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concentrations (MICs) as the bacterial inoculum rises [83], and treatment failures 
have been observed with these antibiotic even with the clear in vitro susceptibility 
[84, 85]. Similarly, the third and fourth generation cephalosporins MICs become 
higher as the inoculum of the infecting organism increases even with the 
apparent in vitro activity against ESBL-producing microbes [86, 87]. Clinical data 
demonstrated that failure rates of cephalosporins are unacceptably high when 
used in treating ESBL-producing organisms [88]; therefore, the Clinical and 
Laboratory Standards Institute (CLSI) recommends that all ESBL-producing 
Klebsiella isolates to be regarded as resistant to all cephalosporins [54].  
 
1.6.2 Treatment of carbapenem resistant Klebsiella  
Even with the critical clinical significance of the carbapenem resistant 
GNB, currently there are no optimal therapeutic approaches available against 
those microorganisms. The reason behind such limitation is the lack of large 
controlled clinical trials testing the effectiveness of available antimicrobial agents 
against diseases caused by the carbapenem resistant bacteria. The 
recommended therapeutic data is generated from small case reports and 
retrospective studies [89, 90]. Empiric treatment against KPC involves the use of 
high dose of carbapenem such as meropenem or doripenem in combination with 
polymyxin B, and continuous infusion of the carbapenem drugs was found to be 
superior to single dose injections [91].  
In addition, preferable outcomes can be achieved upon using combination 
therapy with a third antibiotic that can be added to the empiric treatment including 
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tigecycline, aminoglycoside, fosfomycin, or rifampin [91]. If the bacteria is 
resistant to all aforementioned therapeutic options, then polymyxin B/colistin 
treatment can be used as long as the MIC against the invading pathogen is ≤ 2 
µg/ml [91]; other antibiotic options can be utilized after relaying on the outcomes 
of the in vitro susceptibility testing. Due to the continuously emerging MDR 
bacterial isolates, new therapeutic strategies should always be investigated and 
model systems that allow for testing those treatment approaches should be 
developed.  
 
1.7 K. pneumoniae murine respiratory infection models  
Surrogate animal models were used in biomedical research to answer 
many questions that scientists could not address using in vitro model systems. 
They provided valuable information about the in vivo efficacy of antimicrobial 
agents, host immune response to invading bacteria, and virulence factors 
required by a pathogen to cause disease. K. pneumoniae is capable of colonizing 
multiple anatomical sites within a host; therefore, several surrogate animal 
models have been developed for this critical pathogen including urinary tract, GI 
tract, systemic, intramuscular, and respiratory infection models [92-98].  
K. pneumoniae pulmonary infection can be induced in mice through 
different methods of bacterial inoculation including aerosolization, intranasal, 
surgical intratracheal, nonsurgical intratracheal, and retropharyngeal [99-104]. 
Although intranasal and retropharyngeal infection models are easier to perform 
than intratracheal instillation, these models have some caveats including the 
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possibility of colonizing host upper respiratory tract and bacterial trafficking into 
the GI system limiting investigations directed toward studying targeted 
colonization of host lungs. On the other hand, surgical intratracheal inoculation 
expose the animals to trauma with a possibility of surgical site infection making 
the nonsurgical intratracheal infection model probably the best choice for 
studying lung-specific disease by respiratory pathogens including K. 
pneumoniae. Furthermore, direct-lung instillation of bacteria is a close mimic of 
the typical route of entry for K. pneumoniae into the human host on contaminated 
endotracheal tubes, giving rise to VAP. Mouse model of K. pneumoniae 
respiratory infection recapitulate human disease in which histopathological 
examination following K. pneumoniae inoculation whether through intranasal or 
intratracheal routes revealed that the respiratory disease progress into classical 
bronchopneumonia with a significant influx of polymorphonuclear leukocytes 
(mainly neutrophils), which develops into lobar pneumonia and lung consolidation 
[92, 102, 105-109].  
 
1.7.1 Host response to K. pneumoniae pneumonia  
Host lung possesses several mechanisms of innate immunity against 
insulting pathogens including physical barrier, mucociliary clearance of the 
microbes, epithelial cells immunostimulatory signaling, and activation of resident 
macrophages [110]. Murine models of respiratory disease allowed for the 
identification for the roles of the interleukins (ILs) against K. pneumoniae 
respiratory infection. Mast cell IL-6, an important component of the innate 
  14 
 
immunity, protects the host from pneumonia and sepsis, and IL-6 knockout mice 
are severely susceptible to respiratory and systemic diseases [111]. IL-12 and IL-
23 cytokines play a role in protecting the host against K. pneumoniae respiratory 
disease in which IL-12 is required for INF-ɣ production, while IL-23 is needed for 
IL-17 expression; absence of either of these two cytokines makes the animals 
more susceptible to the disease [112]. IL-17 receptor (IL-17R) is important for 
bacterial defense against K. pneumoniae pulmonary disease by stimulating the 
expression of lung macrophage inflammatory protein (MIP)-2 and via granulocyte 
colony-stimulating factor (G-CSF) [113]. IL-17R knockout mice experienced a 
delayed recruitment of neutrophil into the lung and increased bacterial systemic 
dissemination [113]. Conversely, IL-10 has an adverse effect during the 
pulmonary infection in which it leads to worse disease outcomes and neutralizing 
IL-10 using antibodies improved bacterial clearance, enhanced proinflammatory 
cytokines expression, and increased host survival [108]. This might be due to the 
anti-inflammatory function of IL-10 in which high inflammatory response might 
actually be beneficial for the host in fighting the insulting bacteria.  
Murine models of K. pneumoniae respiratory disease have improved our 
understanding of several host factors involved in innate and adaptive immunity. 
The innate immunity protein lipocalin 2 (Lcn2) protects the host against K. 
pneumoniae pulmonary infection by binding enterobactin disrupting the bacterial 
iron acquisition mechanism and Lcn2-/- mice are more susceptible to the 
respiratory disease [114]. Furthermore, differential and combined roles of Toll-
like receptors (TLRs) in K. pneumoniae pulmonary disease were identified in 
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which TLR4 was found to stimulate the host immune response against low 
bacterial burden while TLR2 might be required later in the disease and/or in 
response to higher bacterial dose [115]. INF-ɣ is critical for host defense against 
K. pneumoniae respiratory infection while the opposite is true when the microbes 
get into the bloodstream [103, 107]. Murine K. pneumoniae respiratory infection 
model revealed the unexpected finding that G-CSF worsen the outcomes of the 
respiratory disease due to increase capsular polysaccharide production instead 
of fighting off the infection through the recruitment and activation of leukocytes 
[94]. Moreover, reduced platelet count correlated with increased mice mortality to 
K. pneumoniae respiratory infection which was associated with increased lung 
injury, bacterial loads in the mice lung, blood, liver, and spleen [109]. 
Overexpression of keratinocyte-derived chemokine (KC) in vivo heightened 
polymorphonuclear leukocyte recruitment into the lung, improved pathogen 
clearance, and increased host survival against K. pneumoniae pulmonary 
infection [116]. Furthermore, irradiated immunocompromised B6D2F1/J mice 
were more susceptible to K. pneumoniae respiratory disease which might serve 
as a useful model in understanding the opportunistic nature of this pathogen in 
susceptible human host [102].  
Murine model of lung disease have also provided some insights into host 
immune response against K. pneumoniae strains that differ in their virulence 
potential. Infecting C57BL/6J mice with a virulent K. pneumoniae ATCC 43816 
strain induced the production of MIP-2, KC, and monocyte chemoattractant 
protein-1 (MCP-1) chemokines while IA565, a K. pneumoniae strain incapable of 
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causing disease in mice, had a basal chemokines levels [95]. In addition, K. 
pneumoniae capsular polysaccharide (CPS) mutant had different inflammatory 
response than its parental wild type strain in which animals infected with the 
capsule mutant had higher levels of INF-ɣ, TNF-α, IL-6, and MCP-1 at different 
time points during the course of the disease [101]. A better understanding of 
host-pathogen interactions during K. pneumoniae respiratory disease could 
facilitate the development of improved therapeutic strategies for treating the 
infection by manipulating the host immune system.    
 
1.7.2 Therapeutic K. pneumoniae lung infection models 
Murine models of K. pneumoniae respiratory infection have given valuable 
insights about the pharmacokinetics of different antibiotics enabling testing their 
efficacy and toxicity in animals before their application in humans. Kanamycin 
aerosol therapy against K. pneumoniae pulmonary infection, inoculated into mice 
lungs by aerosolization, were more effective than intramuscular injection of the 
antibiotic [104]. Ceftazidime treatment was more effective than cefotiam, 
amoxicillin-clavulanic acid, or kanamycin against K. pneumoniae respiratory 
disease caused by intranasal inoculation of the bacteria [117]. 
Surrogate animal models have also facilitated therapeutic studies against 
MDR K. pneumoniae strains. Doripenem was more effective in treating lethal 
lower respiratory tract infection, caused by ESBL-producing K. pneumoniae 
strain, than imipenem, and meropenem in which doripenem reduced 
inflammation, tissue damage, LPS endotoxin release, and bacterial burdens in 
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mice lungs while improving cytokine production [118]. Furthermore, 
combinational therapy was found to be more effective than monotherapy for 
treating pulmonary infection caused by KPC, induced in neutropenic mouse 
model, where the most effective treatment was amikacin plus doripenem [119].  
Murine models of K. pneumoniae respiratory disease were also used to 
monitor the possibility of using alternative therapeutic approaches such as 
dietary supplementation, modulation of host immune response, agents targeting 
bacterial surface structures, and bacterial killing by bacteriophages. Long-term 
feeding of mice with amla reduced bacterial colonization of mice lungs, which 
was coupled with a decrease in malondialdehyde levels, and an increase in 
phagocytic activity of immune cells and nitrite levels [120]. In addition, dietary 
supplementation of omega-3 polyunsaturated fatty acids reduced the severity of 
K. pneumoniae respiratory disease [121]. Peritoneal administration of the 
chemosynthetic peptide IK8L decreased inflammatory cytokines production, 
reduced lung injury, and decreased mortality rate in comparison to sham-treated 
mice [122]. Capsule lytic depolymerase enzyme improved the efficacy of 
gentamicin treatment of K. pneumoniae pulmonary infection in BALB/c mice 
[123]. Treating animals with bacteriophages isolated from MDR K. pneumoniae 
strain lowered bacterial burdens in mice lungs, reduced weight loss, and 
alleviated inflammatory cytokine levels [124]. The development of more 
innovative treatment approaches require the identification of therapeutic targets, 
and thus, it is of a great importance to conduct investigations directed toward 
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identifying virulence factors required by the bacteria to cause the respiratory 
disease.    
 
1.8  Virulence determinants 
1.8.1 Capsular polysaccharide   
 K. pneumoniae capsular polysaccharide (CPS) is a surface structure that 
enclose and protect the bacteria from opsonophagocytosis and subsequent 
killing by host immune cells [125]. Klebsiella encode for a thick capsule 
composed of repeating subunits of four to six sugars (glucose, galactose, 
rhamnose, mannose and fucose), which is frequently coupled with uronic acids 
(as negatively charged components) [14, 126, 127]. Among the other virulence 
factors identified for K. pneumoniae, CPS is the best studied. CPS is a critical 
virulence factor for K. pneumoniae in which deleting that structure increases 
bacterial uptake by cultured macrophages and attenuates their ability to cause a 
respiratory disease in mice [92, 99]. 
The CPS antigens are classified into 77 serotypes in which their 
prevalence varies greatly in different countries [128-135]. The K2 capsular 
serotype is the most common worldwide [128]. K21, K2, and K55 capsular 
serotypes are the most common in North America and Europe, while K1 is the 
major serotype in liver abscess, bacteremia, and septic endophthalmitis in 
Taiwan and in liver abscess isolates in Korea [128-133]. Furthermore, K54 is the 
main serotype isolated from sputum, urine, and blood samples in Australia [134].  
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In general, K1 and K2 capsular serotypes are more associated with 
virulence than non-K1/K2 isolates [136]. The variation in the level of virulence 
noted among K. pneumoniae strains with different capsular serotypes can 
probably be explained by one of two main mechanisms. First, the capsule of the 
non-K1/K2 K. pneumoniae strains contains sugar sequences of L-rhamnose-
alpha-2/3-L-rhamnose or mannose-alpha-2/3-mannose that can be recognized 
by macrophages through either lectin or mannose receptors, which subsequently 
lead to the ingestion and killing of the microorganisms via lectinophagocytosis 
mechanism [137, 138]. On the other hand, these mannose or rhamnose 
sequences are absent from K1 and K2 capsular serotypes making K. 
pneumoniae strains that possess such capsular serotypes resist uptake by 
macrophages, which make those strains probably more virulent to the host [139, 
140].  
The second possible explanation for the variation in the virulence of K. 
pneumoniae strains with different capsular serotypes involves the 
hypermucoviscous phenotype which is associated more frequently with the 
K1/K2 strains than the other serotypes (see section 1.8.1.1) [131]. In addition to 
resisting phagocytosis by macrophages, some capsular serotypes such as K1, 
K2, and K25 have been proposed to play a role in disease by making the 
bacteria more antiphagocytic to neutrophils [140, 141].  
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1.8.1.1 Hypermucoviscosity phenotype 
Some K. pneumoniae strains produce a mucoviscous exopolysaccharide 
structure which is responsible for the hypermucoviscosity phenotype. These 
microbes form sticky colonies on microbiology agar media which can be tested 
by string formation test [142]. A string of more than 5 millimeters in length is 
indicative of a positive test and have been correlated with K. pneumoniae 
invasive infections [143]. The expression of hypermucoviscosity phenotype is 
mediated by rmpA and rmpA2 genes [144]. Proteins encoded by these genes are 
proposed to function as positive regulators that bind the 5’ end for the CPS 
genes [144]. Increased mucoviscosity is predicted to be associated with iron-
limited state, which is the case within a mammalian host [144].  
Independent from the capsular polysaccharide serotypes, isolates that 
illustrate the hypermucoviscosity phenotype or increased capsule production are 
less susceptible to complement-mediated killing than those that do not produce 
excessive capsule [143, 145]. Increased bacterial mucoviscosity is associated 
with high serum resistant and it was found to be present in 98% of isolates 
causing invasive infections in comparison to 17% only in non-invasive strains 
[143]. There is a major correlation between increased mucoviscosity and 
destructive tissue abscess syndrome, including abscess formation in the liver 
and in other anatomical sites [131, 146-150]. Furthermore, hypermucoviscosity 
phenotype was observed in a significantly higher numbers of isolates from 
abscess sites than nonabscess sites again emphasizing the fact that this 
phenotype is associated more with bacterial virulence and invasiveness [146].  




Lipopolysaccharide (LPS) O side chain plays a critical role in K. 
pneumoniae resistance to complement-mediated killing by preventing C1q or 
C3b from attaching to the bacterial cell surface, protecting bacterial membrane 
from damage and subsequent cell death mediated by the complement deposition 
[151-154]. K. pneumoniae LPS mutants were susceptible to complement-
mediated killing, while the same was not true for the CPS which was found to 
play no role in serum resistance [151, 152]. Conversely, some of the K. 
pneumoniae isolates missing the LPS O side chain can still retain resistance to 
complement-mediated killing if the microbes were heavily encapsulated [145]. 
There are other mechanisms in which Klebsiella LPS may contribute in bacterial 
virulence that include intensifying the severity of the respiratory disease by 
increasing the tendency for bacteremia, and by triggering an inflammatory 
response, as an endotoxin, leading to sepsis syndrome and septic shock [155]. 
However, the role of LPS in K. pneumoniae murine respiratory infection models 
is controversial in which two studies demonstrated that the bacteria were 
attenuated upon LPS deletion [155, 156], while a third analysis showed no 
requirement of LPS in bacterial virulence [157]. Such inconsistent outcomes 
might be explained by the differences in the mutants created, where in those 
studies the LPS mutants were created by deleting specific genes rather than the 
whole LPS operon, which might results in variations in the structure and/or 
function of LPS.  
  22 
 
1.8.3 Siderophores  
As one of the Enterobacteriaceae family, Klebsiella require iron for growth 
and due to the limited availability of iron in the microenvironment within the host, 
bacteria have developed mechanisms to compete for and scavenge this 
essential factor [14]. Such mechanisms involve the production of iron chelators 
known as siderophores that compete with host proteins such as transferrin and 
hemoglobin over iron by developing higher affinity for binding ferric iron (Fe3+) 
[158]. K. pneumoniae encodes for four types of siderophores including 
enterobactin, aerobactin, yersiniabactin, and salmochelin which sequester iron 
for the bacteria [114, 159-166]. However, only the production of aerobactin and 
yersiniabactin could be linked with bacterial virulence in murine infection models 
[162, 167-169]. Yersiniabactin is an important siderophore for K. pneumoniae 
that contribute in bacterial virulence during the respiratory disease by enabling 
the bacteria to evade the action of the innate immunity protein lipocalin 2 (Lcn2) 
[114, 159, 170]. On the other hand, salmochelin is a glycosylated form of 
enterobactin which enable the bacteria to evade Lcn2 attachment to the 
siderophore via steric hindrance preventing Lcn2 from neutralizing the iron 
acquisition function of the siderophore [114, 170]. Even though the contribution of 
salmochelin in K. pneumoniae evasion of Lcn2 was demonstrated in ex vivo 
growth assays, the role of this siderophore for bacterial pathology is still unclear 
in which infecting mice with salmochelin isogenic mutant led to variable disease 
outcomes [114, 170].  
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1.8.4 Pili  
K. pneumoniae strains express two morphologically and functionally 
different types of pili including type 1 and type 3 [171]. Type 1 pilus is consists of 
heteropolymeric mannose-binding fibers present in all members of the 
Enterobacteriaceae family, which facilitate bacterial attachment to multiple host 
target cells [172]. The type 3 pili adhesion protein plays an essential role in the 
virulence of K. pneumoniae by allowing the bacteria to adhere to epithelial cells 
of the host including those of the respiratory, urogenital, and intestinal tracts 
[173], which might lead to bacterial colonization of those anatomical sites with 
subsequent proliferation on the host mucosal surfaces leading to clinical 
infections such as pneumonia or pyelonephritis. However, investigations have 
demonstrated that both type 1 and type 3 fimbriae are dispensable for gut and 
lung pathology while only type 1 fimbriae was found to play an important role in 
K. pneumoniae urinary tract infection in mice [174, 175]. In addition to adherence 
to host cells, type 3 pili are essential for biofilm development by K. pneumoniae 
on inanimate surfaces and on human extracellular matrix which leads to the 
establishment of therapeutic-resistant biofilm on indwelling plastic devices such 
as urinary and intravenous catheters [176, 177].  
 
1.9 Specific aims 
K. pneumoniae is an important pathogen capable of causing severe lung 
disease in human. Our overarching goal is to understand the contribution of K. 
pneumoniae virulence factors in the ability of the bacteria to cause the respiratory 
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disease in the host. To conduct our studies we wanted to work with a K. 
pneumoniae strain capable of causing acute lung disease in surrogate animal 
model resembling that of the human, and more importantly a strain that is 
amenable to genomic manipulation. K. pneumoniae ATCC 43816 strain has been 
utilized by different groups to study host response to lung infection but with no 
genomic data available restricting the ability to create mutants, which would limit 
investigations directed toward understanding the contribution of bacterial 
virulence factors in disease. Thus, we have decided to address this scientific gap 
by sequencing the ATCC 43816 strain, perform a genomic comparison with 
previously fully sequenced K. pneumoniae strains including NTUH-K2044, and 
MGH 75878, and compare the relationship between the sequencing data with the 
ability of these strains to cause a respiratory disease in mice. Furthermore, to 
limit the involvement of the upper respiratory tract during the infection, we 
decided to conduct our studies using a lung-specific mouse disease model 
established by our group. We predicted that ATCC 43816 and NTUH-K2044 will 
be more virulent in the mouse model than MGH 78578 since previous findings 
suggest that K. pneumoniae strains with K1 and K2 capsular serotypes are more 
virulent than strains with other capsular serotypes, which might be related to the 
ability of K1/K2 strains to resist phagocytosis by host immune cells. However, K. 
pneumoniae encode for a large genome and capsule is probably not the only 
factor that play a role in virulence; therefore, we propose that comparing the 
sequence of ATCC 43816, NTUH-K2044, and MGH 78578 strains will reveal 
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other factors that might play a role in the ability of the bacteria to cause the 
respiratory disease.   
Due to the increase of MDR K. pneumoniae strains, there is an urgent 
need for the development of new antimicrobial agents, and to create the 
capability of noninvasive monitoring of therapeutic efficacy of clinically important 
drugs against K. pneumoniae lung infection, we decided to engineer a 
bioluminescent bioreporter strain of the bacteria. We propose that such strain will 
enable real-time monitoring of direct effect of antimicrobial agents on the 
organisms themselves instead of inferring the therapeutic efficacy from host 
physiology according to the current practice.  
Lastly, K. pneumoniae causes an acute pneumonia in human but the 
bacteria have only few identified virulence factors as discussed above. In 
contrast, other pathogens capable of causing similar disease to the one caused 
by K. pneumoniae encode for a wide range of virulence determinants. Thus, this 
suggest that there are possibly more virulence determinants that might contribute 
in the ability of K. pneumoniae to cause the pulmonary disease, and the 
identification of these factors will reveal new vaccine and/or therapeutic targets. 
We propose that the identification of virulence determinants required by K. 
pneumoniae to cause the respiratory disease can be achieved using transposon 
sequencing (Tn-seq).    
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CHAPTER 2
MATERIALS AND METHODS 
 
2.1 Bacterial strains and media 
K. pneumoniae strains were cultured routinely in Lennox Broth (LB) or LB agar 
plates at 37oC.  K. pneumoniae was preconditioned for cell culture and animal 
studies by subculturing overnight broth cultures 1:25 into TSBDC [178] for an 
additional 3 hr of growth at 37oC.  Briefly, TSBDC is formulated as a concentrate 
of a 30g/L trypticase soy broth mixed with 5g/L of Chelex 100 in a 1/10th volume, 
which is dialyzed from a 6-8kDa dialysis tubing into a 1x volume of 1% glycerol, 
where the media consists of the small organic compounds which leave the 
dialysis tubing into the 1% glycerol solution.  TSBDC is supplemented with 50mM 
monosodium glutamate immediately prior to use.  The bacterial cultures were 
washed into PBS and their concentration was estimated using OD600 
measurements.  The K. pneumoniae strains used in this study included ATCC 
43816, MGH 78578 (kindly provided by Virginia Miller, UNC), NTUH-K2044 
(kindly provided by Jin-Town Wang, NTUCM and Valley Stewart, UC Davis), and 
CIP 52.145 (Collection of Institut Pasteur).  Where appropriate, antibiotics were 
used at the following concentrations unless otherwise stated: carbenicillin (100 
µg/ml), kanamycin (25 µg/ml), zeocin (100 µg/ml), and gentamicin (20 µg/ml). 
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2.2 Sequencing of K. pneumoniae ATCC 43816 
ATCC 43816 genomic DNA was isolated from ~5x109 bacteria grown in LB broth 
overnight.  The DNA was isolated in TE buffer with 0.5% SDS extraction in the 
presence of proteinase K and RNase, followed by phenol:chloroform:isoamyl 
alcohol (25:24:1 v/v) purification, and alcohol precipitation.  A 1.5 µg aliquot of 
chromosomal DNA was processed for Illumina Next Generation Sequencing 
based on the manufacturer’s instructions.  Briefly, fragmentase (NEB) was used 
to generate 100-300 bp DNA fragments which were end repaired, A-tailed, 
adaptor ligated, and PCR amplified using Phusion.  Two lanes of 51 base reads 
were run to generate 22,422,915 reads of sequencing data, filtered to eliminate 
low quality reads,  and assembled using Velvet [179]. We assembled 1763 
contigs, of which 1550 contigs were >200 bp and were deposited at 
DDBJ/EMBL/GenBank under the accession APWN00000000. The version 
described in this paper is the first version, APWN01000000. The contigs were 
aligned against the non-redundant nucleotide database using BLASTN [180] and 
hits to the full genomes of the NTUH-K2044 and MGH 78578 strains were 
retained separately.  Manual sorting was conducted to identify contigs common 
to or unique from the NTUH-K2044 and MGH 78578 genomes, and unique 
sequence was aligned by BLASTN to identify homology to other bacterial 
species. 
The capsular polysaccharide genetic cluster was manually sequenced to close 
contig gaps between five contigs, as described elsewhere [181], and the 
complete sequence for the ATCC 43816 capsular polysaccharide locus have 
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been deposited with DDBJ/EMBL/GenBank with the accession number 
KJ541664. 
 
2.3 Quantification of capsular polysaccharide production 
Capsule production was quantified for K. pneumoniae from LB overnight cultures, 
as described elsewhere [182]. Briefly, PBS-washed bacteria were enumerated 
and subjected to hot phenol extraction before precipitating the chloroform-treated 
aqueous phase with 0.5M sodium acetate and then 10 volumes of 95% ethanol.  
Polysaccharide was pelleted at 7200g for 5 min after an overnight storage at -
20oC.  The pellet was resuspended in water, and uronic acid was measured from 
capsular polysaccharide preparations using a modified carbazole assay [183], 
with measurement calculated relative to a glucuronolactone standard. 
 
2.4 Generation of capsular polysaccharide mutants 
Capsular polysaccharide mutants were generated for K. pneumoniae strains 
ATCC 43816 and NTUH-K2044 by allelic exchange mutagenesis by initially 
PCR-amplifying upstream (5’) and downstream (3’) 1kb fragments from a gene 
targeted for knock out (Table 1).  The 1kb homologous fragments were 
assembled in pSK (Stratagene) using a HindIII restriction site common to both 
the upstream and downstream fragments.  A HindIII floxed zeocin cassette was 
inserted between the upstream and downstream fragments before the 
assembled construct was moved into an allelic exchange vector, pJMW106, 
which is a KmR variant of pCVD442 [184].  Thus, an XbaI-KpnI fragment 
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containing an in-frame 89.3% coding region deletion of the NTUH-K2044 wzc 
gene was cloned into pJMW106, and electroporated into E. coli strain S17-1 
[185] to yield strain S17-1/pJMW106-NTUH Δwzc::flox-zeo.  Similarly, a XhoI-
SpeI fragment containing an in-frame 90.4% coding region deletion of the ATCC 
43816 manC gene was used to generate the strain S17-1/pJMW106-ATCC 
ΔmanC::flox-zeo.   
Allelic exchange was conducted over two stages, first by bacterial conjugation of 
the allelic exchange vectors from S17-1 to K. pneumoniae and selection of 
CbRKmR merodiploid intermediates, and secondly by counter-selection of the 
suicide vector with 5% sucrose and zeocin.  Confirmation of genome knock-out 
mutagenesis was confirmed on KmS clones using PCR analysis with ‘mut’ 
primers (Table 1) which flank the deletion site. The resulting strains were named 
ATCC ΔmanC and NTUH Δwzc. 
 
2.5 Microscopic analysis of capsule mutants 
Negative staining of K. pneumoniae capsule was conducted using nigrosin stain, 
as described elsewhere [186].  Briefly, LB overnight broth cultures of wild type 
and capsule mutant strains of ATCC 43816 and NTUH-K2044 were mixed 1:1 
with 10% nigrosin and smeared onto 18x18mm coverslips.  The smear was air 
dried before mounting onto a glass slide.  Samples were visualized with a 63x 
objective on a Zeiss Axio microscope, and images were analyzed with Zeiss 
Axiovision Vs40x64 and Imaris x64 (Bitplane). 
 
  30 
 
2.6 Macrophage uptake assay 
Both J774A.1 and RAW264.7 cell lines (ATCC) were cultured in DMEM 
(Invitrogen) supplemented with heat-inactivated 10% fetal bovine serum (FBS, 
HyClone) and seeded into 96 well microtiter plates at a density of 7.5x104 or 
2x105 cells per well, respectively.  Cells were challenged at an MOI of 10 with K. 
pneumoniae ATCC 43816, NTUH-K2044 or MGH 78578, or with capsule 
mutants ATCC ΔmanC or NTUH Δwzc.  At one hour post infection, gentamicin 
was added to eliminate extracellular bacteria (20 µg/ml final, or 1000 µg/ml for 
the GmR MGH 78578 strain).  Gentamicin concentrations were empirically 
determined to kill extracellular K. pneumoniae in DMEM/FBS at >99.99% 
efficiency within a 1 hr window.  At three hours post infection, monolayers were 
washed with PBS, lysed with 0.1% Triton X-100/PBS for 5 min, and serially 
diluted for bacterial enumeration on LB plates 
 
2.7 Macrophage survival assay 
J774A.1 and RAW264.7 macrophages were cultured in 96 well microtiter plates 
as described above.  Triplicate wells of macrophages were infected with K. 
pneumoniae in five replicate plates, and infections were conducted for 1 hr 
before the addition of gentamicin to kill extracellular bacteria, and antibiotic was 
maintained throughout the assay duration.  At time points corresponding to 3, 
4.5, 6, 9, and 12 hr post infection, a microtiter plate of samples was washed in 
PBS before releasing intracellular bacteria from macrophages using a 5 min 
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treatment of 0.1% Triton X-100/PBS.  Samples were serially diluted in PBS and 
plated onto LB plates to enumerate intracellular bacteria.  
 
2.8 Intratracheal infection of mice 
Murine infection studies were approved by the University of Louisville Institutional 
Animal Care and Use Committee in accordance with National Institutes of Health 
guidelines (Protocol # 10069).  Groups of five 8 wk old female BALB/c mice 
(Charles River) were challenged using a non-surgical intratracheal infection 
procedure was developed to minimize trauma during pathogen delivery.  
Intubation-mediated intratracheal (IMIT) inoculations were conducted as 
demonstrated in detail elsewhere [187].  Briefly, isoflurane-anesthetized animals 
received 10 µl of 2% lidocaine anesthetic to the rear of the throat and were 
supported supine on a tilting platform raised to a 45o angle.  Using a fine tipped 
cotton applicator, the tongue was retracted while an otoscope fitted with a cut-
away specula was inserted into the oral cavity to visualize the glottis.  An 18 G 
catheter, cast with a silicone rubber sleeve (10 mm of catheter exposed) was 
used to intubate mice, using a 20 mil guide wire to assist catheter placement.  A 
20 G blunt needle was used to instill a 50 µl PBS bacterial suspension directly 
into the lung via the catheter, followed by a 150 µl volume of air to aid distribution 
of the inoculum.  Infected animals were monitored twice daily for indications of 
moribund disease, at which point they were humanely euthanized by isoflurane.  
Studies were concluded at 14 days.  
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2.9 Bacterial enumeration from key sites of infection 
Groups of five BALB/c mice were infected using the IMIT model with 102.2 CFU of 
either NTUH-K2044 or ATCC 43816.  Moribund mice were euthanized at the 
presentation of lethargy, hunching, and labored breathing.  Mice were euthanized 
by overdose of isoflurane, immediately followed by exsanguination by cardiac 
puncture with a 23 G needle, and the blood was collected to a Microtainer 
(K2EDTA, BD Biosciences).  Lung, liver and spleen were each collected into a 
sterile Whirl-Pak bag (Nasco) and homogenized in 1 ml of sterile PBS, by rolling 
the tissue with a 25ml serological pipette.  Blood and tissue homogenate were 
subjected to detergent lysis with 1% Triton X-100 for 5 min and subsequently 
serially diluted in a 96 well plate.  LB plates were spot-plated with 10 µl aliquots 
of diluted bacterial suspensions, grown for 8 hr at 37oC, and bacterial burdens 
were calculated based on dilution factor, tissue weight, and estimated tissue 
density.  Neutral buoyancy testing in glycerol solutions revealed that the 
estimated tissue densities for lung, liver, and spleen were 1.03, 1.08, and 1.06 
g/ml, respectively. 
 
2.10 Creating the bioluminescent JSKP001 strain 
The bioluminescent JSKP001 strain was created by the insertion of a lux operon 
in-between fusA and yeeF genes using two-stage allelic exchange mutagenesis 
as described previously [99]. Briefly, 1 kb upstream (5’) and downstream (3’) 
fragments flanking the insertion site was PCR amplified from ATCC 43816 
genome using primers listed in table 1 and cloned into pSK. A DNA fragment of 
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407-bp containing a stem loop terminator and rplU promoter was also generated 
from K. pneumoniae genome and combined with the 5’ fragment using BsiWI cut 
site engineered in both fragments. Both 5’ and 3’ handles were assembled in 
pGSVS suicide vector on either ends of the lux operon generating the pGSVS-
Kpin-PrplU-lux plasmid. A loxP-flanked (floxed) zeocin antibiotic marker (Sh ble) 
was PCR amplified and cloned into pSK creating pSK-floxZeo. The floxZeo 
fragment was subcloned between the 3’ handle and luxC open reading frame of 
the lux operon in the plasmid pGSVS-Kpin-PrplU-lux creating the construct 
pGSVS2-Kp ATCC-PrplU-lux-floxZeo. The constructed pGSVS2-Kp ATCC-
PrplU-lux-floxZeo vector was electroporated into S17-1, conjugated into K. 
pneumoniae ATCC 43816, and using two-stage allelic replacement, the ATCC 
43816::Kp ATCC-PrplU-lux-floxZeo strain was created and named WKP001. The 
zeocin marker was removed from the WKP001 strain using cre recombinase 
system. Briefly, a 1-Kb fragment containing galF gene was PCR amplified, 
cloned into pSK giving the plasmid pSK-galF, and then the same fragment was 
subcloned into pKSVS-PtolC-cre using SpeI/NotI restriction sites creating the 
vector pKSVS-PtolC-cre-galF. S17-1::pKSVS-PtolC-cre-galF was conjugated into 
WKP001 and with the trans expression of cre, the zeocin cassette was removed 
generating the JSK001 strain. 
 
2.11 In vitro proliferation of JSKP001 and ATCC 43816   
Overnight cultures of the JSKP001 and ATCC 43816 strains were diluted 1000 
fold in LB broth and 100 µl aliquots (in triplicate for each strain) were transferred 
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into Greiner 96-well black plate with clear bottom. A kinetic read was performed 
in Synergy™ H1 monochromator-based multi-mode microplate reader (BioTek) 
where the machine was setup to take OD600 and bioluminescence measurements 
at 10 minute intervals for 4 hours at 37oC with agitation.  
 
2.12 In vitro correlation of JSKP001 bioluminescence and bacterial 
numbers 
Overnight culture of JSKP001 strain was diluted 1000 fold into 4 ml LB broth 
media and grown for 3 hr at 37oC with agitation in an orbital shaker (200 rpm). 
100 µl aliquots (in triplicate) were taken at 30 minute intervals for 
bioluminescence estimation using Synergy™ HT Multi-Detection Microplate 
Reader (BioTek) and for bacterial numbers enumeration.  
 
2.13 In vivo fitness and real-time monitoring of K. pneumoniae in mice 
All animal studies were approved by the University of Louisville Institutional 
Animal Care and Use Committee (IACUC no. 10069 and 13059). Two groups of 
five female albino C57BL/6J mice 8-10 weeks of age (Jackson Laboratories) was 
infected intratracheally with ATCC 43816 (104.95 CFU), and JSKP001 (104.91 
CFU) as described elsewhere [187]. Bioluminescence imaging (BLI) was 
conducted using PhotonIMAGER Optima system (BIOSPACE LAB) and health 
checks were performed twice daily. The animals were humanely euthanized 
upon meeting heart rate of 400 beat per minute (BPM) or below, monitored using 
MouseOx Plus (STARR Life Sciences Corp.), in addition to illustration of clear 
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signs of disease including slow to no movement, minimum resistance upon 
handling, hunching, and shortness of breath (SOB). The euthanasia was 
conducted with isoflurane followed by exsanguination using cardiac puncture. 
Upon reaching moribund disease, blood, BAL, lung, liver, spleen, and kidneys 
were collected and processed for bacterial enumeration as described previously 
[99]. In vivo monitoring of bacterial colonization of host lungs for each animal was 
performed by BLI, where region of interests (ROIs, 5 cm2) were drawn on mice 
thoracic cavity (imaged for 1 minute on dorsal position) with technical 
background subtraction. Two standard deviation limit of detection (LOD) was 
established from uninfected mice (biological background).  
 
2.14 Measuring the correlation between bioluminescence and bacterial 
numbers within host tissues 
Female albino C57BL/6J mice were infected with 103 – 105.2 CFU with JSKP001 
strain and lung, liver, spleen, kidneys, 100 µl BAL, and 100 µl blood samples 
were collected from mice that developed moribund disease (n = 36). Bacterial 
burdens were estimated by measuring bioluminescence in Greiner 24-well black 
plates using PhotonIMAGER Optima system followed by processing of samples 
for bacterial enumeration as described previously [99]. Correlation between in 
vivo bioluminescence in life and bacterial burdens were performed by drawing 5 
cm2 ROIs on animals’ thoracic cavity right before euthanasia to estimate 
bioluminescence levels and bacterial loads were enumerated from lung 
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homogenates following euthanizing the moribund mice (n = 29) and processing 
the tissues as described above.   
 
2.15 MicroChem-Plus killing assay  
Eighteen hours overnight bacterial culture was diluted 25 fold in LB and the 
microbes were grown to exponential phase for 1 hr at 37oC with agitation. The 
bacteria were centrifuged at 15000g for 1 minute, the supernatant was decanted, 
the pellets were resuspended in sterile PBS, and mixed in 1:1 ratio with serially 
diluted 2x MicroChem-Plus disinfectant in Greiner 96-well black plate with clear 
flat bottom. 10 min kinetic read was immediately performed in SyngeryTM H1 
plate reader at room temperature (~24oC) where the machine was setup to 
measure bioluminescence every minute and following 11 min of incubation, the 
bacteria were rapidly diluted and spot plated on LB agar plates for enumeration. 
 
2.16 In vitro bacterial growth inhibition by meropenem  
Overnight bacterial suspension was diluted 25 fold in LB broth and the microbes 
were grown further to exponential phase at 37oC for 1 hour with agitation. The 
exponentially growing bacteria (108.9 CFU/ml) were diluted 50 fold in LB and 
mixed in 1:1 ratio with 2x serially diluted meropenem in 96-well black Greiner 
plate with clear bottom. A kinetic read in SynergyTM H1 plate reader was 
performed at 37oC where OD600 and bioluminescence measurements were taken 
every 5 min for 8 hr. The 50% effective dose (EC50) of the drug was estimated at 
the 8 hr time point using GraphPad Prism 6 software.  
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2.17 Meropenem therapeutic study 
Four groups of female albino C57BL/6J mice (8-10 weeks of age) were infected 
intratracheally with a lethal dose (104.9 CFU) of K. pneumoniae JSKP001 strain 
and three hours post infection, three groups was subcutaneously introduced with 
either 96, 200, or 400 mg/kg/day meropenem prepared in PBS (HyClone) while 
the fourth group was injected with vehicle only (PBS). Injecting the therapeutic 
treatments, monitoring animals’ health status (including heart rate measurement), 
and optical diagnostic imaging was performed q12h. The animals were monitored 
for one week post infection and humanely euthanized upon meeting the endpoint 
criteria explained earlier. The 96 mg/kg/day group was conducted in a separate 
study from the 200, and 400 mg/kg/day treatment groups.  
 
2.18 Creating the bioluminescent manC and vgrG mutants  
The bioluminescent manC and vgrG mutants were created using allelic exchange 
mutagenesis as described previously [99]. The JSKP001ΔmanC strain was 
created from the previously made strain ATCC 43816 ΔmanC [99], where a lux 
operon was inserted into this strain using the plasmid pGSVS2-Kp ATCC-PrplU-
lux-floxZeo transformed into ATCC through conjugation from S17-1 followed by 
two step allelic replacement generating the strain WKP001ΔmanC. The insertion 
of the lux operon into bacterial genome was confirmed by testing 
bioluminescence production using SynergyTM HT plate reader and/or 
PhotonIMAGER Optima system. The zeocin marker was removed from the 
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WKP001ΔmanC using cre recombinase system as described above creating the 
strain JSKP001ΔmanC. On the other hand, the bioluminescent vgrG mutants 
were made in the JSKP001 strain. 1 kb upstream (5’) and downstream (3’) 
fragments from vgrG1, and vgrG2 genes were PCR amplified and combined in 
pSK (table 1). Zeocin cassette was inserted in-between the handles using HindIII 
cut site, shared between the two fragments, creating the plasmids pSK-vgrG1-
flox-zeo and pSK-vgrG2-flox-zeo followed by subcloning the assembled vgrG-
flox-zeo fragments into pJMW106. The resulted constructs were transformed into 
S17-1 E. coli competent cells creating the strains S17-1/pJMW106-vgrG1-flox-
zeo and S17-1/pJMW106-vgrG2-flox-zeo. These vectors were transformed into 
JSKP001 by conjugation and following two step allelic replacement the 
JSKP001ΔvgrG1-flox-zeo and JSKP001ΔvgrG2-flox-zeo strains were generated. 
The zeocin markers were removed from those strains using the cre recombinase 
system described previously creating JSKP001ΔvgrG1 and JSKP001ΔvgrG2 
strains. The bioluminescent vgrG1/2 double knockout was generated in the 
JSKP001ΔvgrG2 strain using the same steps.  The deletion of the vgrG genes 
were confirmed with PCR using vgrG ‘mut’ primers (table 1).  
 
2.19 Testing the fitness of the JSKP001ΔmanC in vivo 
Female albino C57BL/6J mice (8-10 weeks of age) were infected with either 
JSKP001 (104.1 CFU) and JSKP001ΔmanC (108.0 CFU) using IMIT and 
monitored for two weeks for the development of moribund disease which consist 
of a heart rate of 400 bpm or below in addition to illustration of severe illness 
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including slow movement, reduced resistance upon handling, hunching, and 
SOB. Moreover, bacterial proliferation within mice lungs were monitored using 
PhotonIMAGER Optima system every 12 hr. Animals were euthanized upon 
meeting moribund disease or two weeks post infection and blood, BAL, lungs, 
liver, spleen, and kidneys were collected for bacterial burden estimation.  
 
2.20 Monitoring JSKP001ΔmanC early clearance in vivo 
Eight to ten weeks of age female albino C57BL/6J mice were infected with 107.9 
CFU of the JSKP001ΔmanC strain using IMIT. Bioluminescence imaging (BLI) 
monitoring bacterial lung colonization was initiated right after the infection (0.5 
hour post infection) followed by imaging the mice at 3 hr intervals. The animals 
were euthanized 6.5 hours post infection, lungs were collected, and processed 
for bacterial burden estimation as previously described.   
 
2.21 Tracking JSKP001 replication within cultured macrophages  
Time course gentamicin protection assay was performed as described above. 
Briefly, RAW264.7 murine macrophages were infected with MOI of 10 with the 
JSKP001 and ATCC 43816 (in triplicate) using four replicate Greiner 96-well flat 
bottom black plates. Gentamicin treatment was performed 1 hr post infection to 
kill all extracellular bacteria. Bacterial loads within the cells were estimated at 3, 
4.5, 6, and 9 hr time points by measuring bioluminescence using SynergyTM HT 
plate reader followed by lysing the cells with 0.1% Triton X-100 (in PBS) for 5 min 
for bacterial enumeration.  
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2.22 Creating bioluminescent K. pneumoniae strains with different 
promoters 
pSK-Kp5’-PtolC plasmid was reverse PCR amplified adding the sequence for the 
synthetic EM7 promoter and ATCC 43816 frr, ompC, and rpoD promoters 
together with NheI restriction sites (table 1), which then got ligated and 
transformed into DH10B creating the strains DH10B/pSK-Kp5’-PEM7, 
DH10B/pSK-Kp5’-PrpoD, DH10B/pSK-Kp5’-Pfrr, and DH10B/pSK-Kp5’-PompC. 
The Kp5’ handle with the different promoters were subcloned into pGSVS using 
EcoRI/PspOMI cut sites, and then larger fragments including the Kp5’ handles 
together with the different promoters and part of the lux operon were subcloned 
into pJMW106-Kp-nif-PtolC-lux-floxZeo replacing the PtolC promoter with either 
EM7, frr, rpoD, or ompC promoters creating the vectors pJMW106-Kp-nif-PEM7-
lux-floxZeo, pJMW106-Kp-nif-Pfrr-lux-floxZeo, pJMW106-Kp-nif-PrpoD-lux-
floxZeo, and pJMW106-Kp-nif-PompC-lux-floxZeo. Those constructs were 
transferred from S17-1 into ATCC 43816 by conjugation and a two-step allelic 
replacement took place as described above creating the strains ATCC::Kp 
ATCC-PEM7-lux-floxZeo, ATCC::Kp ATCC-Pfrr-lux-floxZeo, ATCC::Kp ATCC-
PrpoD-lux-floxZeo, and ATCC::Kp ATCC-PompC-lux-floxZeo. Cloning of the 
different promoters into the aforementioned plasmids were confirmed by 
sequencing, and the creation of the different bioluminescent strains were 
validated by testing light emission using SynergyTM HT plate reader and/or 
PhotonIMAGER Optima.  
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2.23 Monitoring the bioluminescent K. pneumoniae strains replication 
within macrophages 
J774A.1 cells (seeded in Greiner 96-well black plate with flat bottom) were 
infected with MOI of 10 with the strains ATCC::Kp ATCC-PEM7-lux-floxZeo, 
ATCC::Kp ATCC-Pfrr-lux-floxZeo, ATCC::Kp ATCC-PrpoD-lux-floxZeo, and 
ATCC::Kp ATCC-PompC-lux-floxZeo and the plate was incubated at 37oC. 
Extracellular bacteria were killed 1 hr post infection using gentamicin treatment 
as described above. Intracellular bacteria were monitored by measuring 
bioluminescence at 2, 3, 4, 5, 6, 9, and 12 hr using SynergyTM HT plate reader.  
 
2.24 Estimation of intracellular bacteria within host lungs 
Albino C57BL/6J mice were infected with JSKP001 (105.1 CFU) using IMIT and 
their health status was monitored every 12 hr. Animals were euthanized 43 hr 
post infection and lungs were collected for total and intracellular bacterial 
enumeration. The tissues were dissociated into single cell suspension using 
0.3% collagenase treatment (in PBS) for 2.5 hr at room temperature followed by 
running the homogenates through cell strainer to separate the tissue clumps into 
single cells. A portion of the cell suspension was treated with 1% Triton X-100 to 
release intracellular microbes for total bacterial estimation. Intracellular bacteria 
were estimated using gentamicin protection assay and a newly developed 
filtration technique. The amount of viable cells in the suspension was estimated 
using hemocytometer following trypan blue staining. Gentamicin was used on 106 
cells suspended in 1 ml PBS to eliminate extracellular bacteria using 1 mg/ml 
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treatment which we determined that it would kill 99.98% of the bacteria at room 
temperature following the 1 hr treatment (Figure 1). The cells were spun down at 
100g for 5 min and a couple of PBS washes were preformed to get rid of the 
antibiotic. The cell pellet were resuspended in PBS, and lysed for bacterial 
enumeration. For estimating the intracellular bacteria using the filter technique, 
106 cells in 1 ml PBS were passed through 5 micron filter assembled in swinnex 
filter holder and two PBS washes were performed to get rid of the extracellular 
bacteria. To release the intracellular microbes trapped in the membrane, 1% 
Triton X-100 (in PBS) treatment was performed, the eluted bacteria was 
collected, and enumerated. Following preforming the gentamicin killing and the 
filter techniques, the percentages of intracellular bacteria to the total microbial 
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Figure 1. Gentamicin killing of K. pneumoniae at room temperature. 
2x106 CFU/ml bacterial suspension in PBS was prepared using overnight culture 
(18 hr) of ATCC 43816 and treated with a serially diluted gentamicin (from 17.34 
to 1000 µg/ml). The bacterial suspensions were incubated with the different 
antibiotic concentrations for 1 h at room temperature (22oC) and following the 1 h 
treatment, the bacteria were centrifuged at 15000g, and two PBS washes were 
performed to get rid of the antibiotic. The bacteria were spot plated on LB plates 
for bacterial enumeration. 
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2.25 Tn-seq study  
2.25.1 Creating transposon library in JSKP001 
pSAM-RF-Km plasmid was created from the vector pSAM-DKm (kindly provided 
by Dr. Yoder-himes) by deleting the bla gene to eliminate the carbenicillin 
resistance. pSAM-DKm was digested using PvuI/ApaLI restriction enzymes, the 
ends were blunted using DNA Polymerase I, Large (Klenow) Fragment, ligated 
for overnight using T4 DNA ligase, and transformed into E. coli S17-1 creating 
the strain S17-1/pSAM-RF-Km. pSAM-RF-Km plasmid was transferred into 
JSKP001 using conjugation (4:1 ratio) at the 37oC for 1 hour followed by 
spreading 100 µl aliquots of the conjugation mixture on 42 LB plates with 
Cb100Km25 selection and growing the microbes at 37oC for 14 hours. A total of 
20000 (or 104.2 CFU) transposon mutants were collected (4x genome coverage 
of JSKP001), grown in LB broth for overnight, and stored in the -80oC in 25% 
glycerol.  
 
2.25.2 Infecting albino C57BL/6J mice with the generated Tn-seq library 
Female albino C57BL/6J mice (8-10 weeks) were infected with 104.8 CFU of the 
JSKP001 transposon mutants using IMIT. Bacterial lung colonization was 
monitored using PhotonIMAGER Optima system every 12 hr and then we 
switched into 3 hr monitoring upon meeting in vivo lung bioluminescence ≥ 106.5 
ph/s. Mice were euthanized after reaching or exceeding in vivo lung 
bioluminescence of 108 ph/s. Lungs were collected and processed as described 
above for bacterial enumeration. Bacterial inoculum used to infect the animals 
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(input library) and bacteria extracted from tissue homogenates (output libraries) 
were inoculated into LB broth and cultured for overnight at 37oC with agitation 
(200 rpm) to expand the bacterial libraries. On the following day, the cultures 
were centrifuged and the bacterial pellets were frozen and stored at -80oC to be 
used for genomic DNA extraction and the subsequent steps for Tn-seq analysis 
including MmeI digest, agarose gel electrophoresis, DNA purification, adaptor 
ligation, PCR amplification, and massive parallel sequencing (MPS). 
 
2.26 Testing the virulence of the vgrG mutants in single strain infection 
model 
Female albino C57BL/6J mice were infected with 104.8 - 104.9 CFU of the 
JSKP001, JSKP001ΔvgrG1, JSKP001ΔvgrG2, and JSKP001ΔvgrG1/2 using 
IMIT. Animals were monitored for the development of moribund disease and 
euthanized upon meeting heart rate of 400 bpm or below in addition to the 
illustration of clear signs of illness including reduced mobility, minimum 
resistance upon handling, SOB, and hunching. Upon euthanasia, blood, BAL, 
lung, liver, spleen, and kidneys were collected for bacterial burden estimation as 
described above.  
 
2.27 Testing vgrG mutants fitness using in vivo competition study 
ATCC 43816 was inoculated into female albino C57BL/6J mice in 1:1 ratio with 
JSKP001, JSKP001ΔvgrG1, JSKP001ΔvgrG2, or JSKP001ΔvgrG1/2 (104.9 – 
105.4 CFU). In vivo bacterial colonization of mice lungs were monitored using 
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PhotonIMAGER Optima system every 12 hr, animals were euthanized upon 
meeting heart rate of ≤ 500, and blood, lung, liver and spleen tissues were 
collected for bacterial burden estimation. The JSKP001 strains were 
distinguished from the non-luminescent ATCC 43816 bacteria by taking a picture 
of the LB plates using PhotonIMAGER Optima system. The competitive indexes 
were calculated by dividing ratios of the JSKP001 strains to ATCC 43816 in the 
tissues by the ratios of the JSKP001 strains to ATCC 43816 in the inoculums.  
 
2.28 Statistical analysis  
Statistical analysis of data sets was conducted by One-way ANOVA with Tukey 
post-test of log-transformed data, survival data was conducted using Log-rank 
(Mantel-Cox) and Gehan-Breslow-Wilcoxon Tests (GraphPad Prism 5).  Probit 
analysis (StatPlus 2009 Professional) was used to calculate the LD50 (50% Lethal 
Dose) and both the upper (UCL) and lower (LCL) reliable interval values in 
addition to meropenem ED50 (50% effective dose). In vitro growth curves were 
analyzed using unpaired student T-test, using log transformed OD600 reads. 
Bacterial burden in tissues of animals infected with either JSKP001 or ATCC 
43816 strains were compared by Two-way ANOVA with Bonferroni post-test of 
log transformed data. Unpaired student T-test was used to analyze the difference 
in meropenem EC50 (50% effective concentration) values estimated by OD600 and 
bioluminescence against JSKP001 (GraphPad Prism 6).  
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Table 1. Primers used in this study. 
5’ ATCC manC XbaI (+) CTGCTCGAGATTACCAAAGATATCTTCACCAAGAAGGATGA
AG 
5’ ATCC manC HindIII (-) GTAAAGCTTGCGAGACATCGGCCAGAGACGAC 
3’ ATCC manC HindIII (+) GAAAAGCTTGAGATCCAGTCGGGGTCGTACCTC 
3’ ATCC manC KpnI (-) GTGACTAGTTTTCGCTCCCGGCTGCTTCTGC 
ATCC manC mut (+) GTTATTCTACAATAAACTGACCAAGTCATCTTGTTTCCTCTC
CTTCG 
ATCC manC mut (-) CTATCTTCCCGGGTTTCAGAAATTCGCCGTAGGC 
5’ NTUH wzc XbaI (+) CGTTCTAGAGCATAACGGTAAAGATACTAAGATCTCCTTATA
TGC 
5’ NTUH wzc HindIII (-) CAAAGCTTTATGATCAATAACTTCACCAATTAAACGACCTAG
ATCGATCC 
3’ NTUH wzc HindIII (+) CAAAGCTTTCGATGTTGCTAAAAATAGATTGGAACATAGCG
GTGTTATAG 
3’ NTUH wzc KpnI (-) CTGGTACCTAATAATGAGGAGAACATTACCATAAAACGAGA
TGTATTTCG 
NTUH wzc mut (+) GGCAAAACTATGTTATTCGGACATTGGATAGGGCAACGAG 
NTUH wzc mut (-) CATTAATCGCAAGGCCAAATCCTTGTGATAATAGCATGCTT
AGTATTC 
5’ ATCC vgrG1  XbaI (+) GGTCTAGAAACCGCGCTTATCGCCGTCCAG 
5’ ATCC vgrG1 HindIII (-) CCAAGCTTCACATCCCTTCACCGAAAGCAGGTG 
3’ ATCC vgrG1  HindIII (+) CAAAGCTTGTCTGAAACGGGCACAGGAAATCGCTC 
3’ ATCC vgrG1  KpnI (-) CCGGTACCCATTTTGGAGGCACACCAAAATACCC 
ATCC vgrG1 mut (+) CCGTAACGTCGACAGTCTGCTCAATCAGCAGATC 
ATCC vgrG1 mut (-) CTCAGGTAGCCCTTGATATAGCGACTGCCACATC 
5’ ATCC vgrG2 XbaI (+) CGTCTAGATGATCGTGGTGGCAGGCCATACC 
5’ ATCC vgrG2  HindIII (-) GCAAGCTTGTAACGGTTAAGGGTGGTGCCGGTAATTATTG 
3’ ATCC vgrG2  HindIII (+) CGAAGCTTCGTAATACTTACGCGGATTTGCTCGATGAC 
3’ ATCC vgrG2  KpnI (-) GCGGTACCCCAGTACTCATCGAGCATATTGTGTC 
ATCC vgrG2 mut (+) GGGTTACCTTTTAGTTACGAAACTCCTGGTGGGGTATC 
ATCC vgrG2 mut (-) CGATTTTTGCGCCTTTTCGATGGCTCGATATACCGC 
pSK-Kp5'-PtolC NheI (-) CCGGCTAGCAAAAACGGGAGCCCATCGGCTC 
























CORRELATION OF KLEBSIELLA PNEUMONIAE COMPARATIVE GENETIC 




Klebsiella pneumoniae ssp. pneumoniae (K. pneumoniae) is responsible 
for emerging infectious disease and is a causative agent of both nosocomial and 
community acquired pneumonia (CAP) worldwide.  The epidemiology of K. 
pneumoniae is complex, involving ecological persistence as well as carriage in 
both animal and human populations [188].  Carriage of K. pneumoniae is 
frequently associated with colonization of the upper respiratory tract or 
gastrointestinal (GI) tract, with the potential for GI tract amplification of antibiotic 
resistant strains of K. pneumoniae following antibiotic therapies [189].  K. 
pneumoniae opportunistically infects a variety of mucosal surfaces with the 
primary sites of infection including the urinary tract and the lower respiratory tract 
(LRT) [190].   
                                                                
1 Fodah, R. A., Scott, J. B., Tam, H. H., Yan, P., Pfeffer, T. L., Bundschuh, R., & Warawa, J. M. (2014). 
Correlation of Klebsiella pneumoniae comparative genetic analyses with virulence profiles in a murine 
respiratory disease model. PLoS One, 9(9), e107394. doi:10.1371/journal.pone.0107394 
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K. pneumoniae pneumonia is a fatal disease with mortality rates of up to 
22.7% [48, 191].  The incidence of K. pneumoniae pneumonia in the United 
States is more commonly associated with nosocomial acquisition of disease 
rather than environmental sources [14, 192], as Klebsiella is thought to contribute 
to only 1% of CAP in North America [193-195].  K. pneumoniae is the fifth most 
prevalent nosocomial bacterial pathogen in the United States for infections 
associated with UTIs, VAP and central line-associated bacteremia, and accounts 
for 6% of all nosocomial bacterial disease [196].  The emergence of K. 
pneumoniae as a nosocomial pathogen in the US and Europe may be due in part 
to the acquisition of antibiotic resistance markers providing a selective advantage 
in hospital settings, with particular concerns growing over an increasing 
prevalence of carbapenemase-expressing K. pneumoniae (KPC) strains [197].  
Well characterized outbreaks of KPC dating back to 1988 have still not led to 
effective clinical diagnosis or control of these emerging pathogens in the US over 
20 years later [80, 198].  Recently instated surveillance programs have begun to 
characterize the increasing threat of K. pneumoniae in the US health care 
system, where it is understood that the threat of K. pneumoniae, and in particular 
KPC, may be underestimated, particularly in long-term acute care facilities [199].   
Several virulence determinants are important in mediating the virulence of 
K. pneumoniae in the lung, including capsular polysaccharide, 
lipopolysaccharide, enterobacterial common antigen, OmpA, OmpK36, the 
AcrAB efflux pump, the regulator RamA, the biofilm related factor YciI, and 
yersiniabactin [92, 156, 159, 200-204]. However, additional undescribed systems 
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may participate in K. pneumoniae virulence.  To this end, numerous sequencing 
efforts have begun to characterize the genomes of K. pneumoniae strains 
including the first whole genome sequences of the clinical isolates MGH 78578 
and NTUH-K2044 [205], and the more recent release of whole genome 
sequences of the strains HS11286 [206] and KCTC 2242 [207].  Comparative 
genetic analyses have successfully led to the identification and characterization 
of a novel allantoin metabolism locus required for GI tract disease which is 
present in the genome of NTUH-K2044, but absent from MGH 78578 [93].  
The ATCC 43816 strain has been the focus of several studies 
characterizing the respiratory disease caused by K. pneumoniae [92, 200, 208], 
however this strain has not been sequenced, thus limiting investigations directed 
at identification of novel virulence determinants.  To address this scientific gap, 
we have performed whole genome sequencing of ATCC 43816 to begin the 
characterization potential genomic differences relative to the sequenced K. 
pneumoniae strains.   
We also decided to investigate host-pathogen interaction for the 
sequenced K. pneumoniae strains NTUH-K2044 and MGH 78578, for which little 
is known about their ability to cause respiratory disease or interact with 
professional phagocytes.  We developed a novel pulmonary-specific delivery 
respiratory disease model in which to examine sequenced K. pneumoniae 
strains.  Finally, we have characterized the ability of K. pneumoniae to modulate 
uptake and persist within multiple cultured murine macrophage cell lines.    
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3.2 Results 
3.2.1 Whole genome sequencing of strain ATCC 43816 
K. pneumoniae ATCC 43816 is a well-studied strain, capable of causing a 
moribund respiratory disease in mouse models. However, limited genomic data is 
available to support future investigations of K. pneumoniae pathogenesis, thus 
we decided to perform whole genome sequencing.  Next Generation Sequencing 
was used to sequence the ATCC 43816 genome, which was subsequently 
assembled into 1763 contigs consisting of 4.207 MB of sequence data 
(accession number APWN00000000).  To investigate the genetic relatedness of 
sequenced K. pneumoniae strains, the ATCC 43816 genome was aligned to the 
complete genome sequences of the NTUH-K2044 and MGH 78578 strains 
(Figure 2A and B, respectively).  A total of 1676 contigs (4.128 MB) aligned with 
the NTUH-K2044 chromosome representing 78.7% genome coverage.  Similarly, 
1668 contigs (4.098 MB) mapped to 77.1% of the MGH 78578 genome, which 
includes two contigs mapping to the toxin-antitoxin system of the pKPN4 plasmid.  
We identified no additional sequence homology to K. pneumoniae plasmids, and 
the homologous toxin-antitoxin system is maintained on the chromosome for the 
NTUH-K2044 strain, suggesting that K. pneumoniae strain ATCC 43816 does not 
possess plasmids.   
A high degree of genetic conservation was observed between the three K. 
pneumoniae strains with 96.3% of ATCC 43816 sequence mapping to both MGH 
78578 and NTUH-K2044.  However, 69.71 kb of ATCC 43816 contigs uniquely 
map with the NTUH-K2044 genome and 44.67 kb with the MGH 78578 genome 
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(1.66% and 1.06% total sequence data, respectively).  While MGH 78578 shares 
primarily metabolic and hypothetical proteins with ATCC 43816, NTUH-K2044 
shares the virulence-associated yersiniabactin biosynthetic operon, a Type IV 
secretion system, an iron transport system, a CRISPR locus, and an acetonin 
catabolism locus (Table 2).  Given the conservation of known virulence 
determinants between ATCC 43816 and NTUH-K2044, the data suggests that 
NTUH-K2044 may share the same virulence potential as ATCC 43816 in disease 
models.  Conversely, MGH 78578 lacks several of the virulence determinants 
previously identified as critical to the disease potential of ATCC 43816 in murine 
respiratory disease models, suggesting that MGH 78578 may have a reduced 
virulence in these models, though MGH 78578 is notably a clinical lung isolate 
from a presentation of pneumonia.  
We also identified novel genetic sequences unique to ATCC 43816, and 
not present in either NTUH-K2044 or MGH 78578, notably including two 
bacteriophages, one of which is homologous to a bacteriophage found in the 
enteric Escherichia coli strain UMN026, and the other to the upper respiratory 
tract (URT) pathogen Klebsiella rhinoscleromatis strain ATCC 13884 (Table 2).  
Little has been reported regarding the clinical history of ATCC 43816, however 
the presence of both gastrointestinal (GI) and URT-related bacteriophages 
suggests that this K. pneumoniae strain may have previously been resident of 
both host niches.   
Next Generation Sequencing provided an estimated 78% coverage of the 
ATCC 43816 genome, however sequencing of the capsular polysaccharide 
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biosynthetic locus was under-represented at 22% coverage (determined 
retrospectively).  Given the importance of capsule as a virulence determinant, we 
completed sequencing of a 34.6 kb region which includes the capsule locus as 
well as an adjacent region (wzm to wbbO) reported to be required for LPS 
biosynthesis (Figure 3) [209].  The K2 capsular polysaccharide locus shares 
broad homology to sequenced capsule loci from the galF to wzc and rfbP to uge 
genes, but shares specific homology over the central orf7 to orf13 genes to a 
subset of sequenced K. pneumoniae strains of K2 serotype.  Homology over the 
entire capsule locus is therefore highest (99% identity) to that of the recently fully 
sequenced strains CG43 (Accession CP006648), KCTC 2242 (CP002910), and 
Kp52.145 (FO834906), and also to the partially sequenced capsule biosynthetic 
loci of VGH525 (Accession AB371296) and Chedid (D21242).  The central region 
of the capsule loci encodes for the antigenic diversity of capsules, which has 
previously supported the use of PCR as a methodology to identify capsule 
serotype [210, 211].   
 
3.2.2 Characterization of capsule production  
K. pneumoniae capsular serotypes influence the virulence potential of 
strains, as could the regulated production of capsule.  Thus, we investigated 
whether differences exist in the amount of capsule produced by the three clinical 
strains examined in this study.  K. pneumoniae were examined for their ability to 
produce capsule from LB overnight cultures.  We found that ATCC 43816, 
NTUH-K2044 and MGH 78578 strains produced 9.7, 13.5, and 6.1 fg/CFU of 
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capsule, respectively.  As a control, we also measured capsule production from 
previously characterized strain 52.145 which produced 21.7 fg/CFU of capsule in 
our studies, consistent with 52.145 being a significant producer of capsule [182].  
Our measurement of NTUH-K2044 capsule production is consistent with 
previously reported levels of 17.3 fg/CFU of capsule from overnight LB cultures 
[212]. Thus, of the sequenced strains studied in this work, NTUH-K2044 
produced the greatest amount of capsule at levels 1.4 and 2.2 fold greater than 
ATCC 43816 and MGH 78578.  Similar amounts of capsule were measured from 
strains grown to mid-exponential phase in TSBDC, suggesting that media and 
growth phase do not significantly impact capsule production. 
 
3.2.3 Cell culture model 
K. pneumoniae is internalized by a variety of host cell types both in vivo 
and in cell culture models, thus we investigated whether the three study strains 
exhibit differences in uptake rates in cultured murine macrophages.  Given that 
capsular polysaccharide has been reported to mediate an antiphagocytic 
phenotype, we also generated capsular polysaccharide mutants of ATCC 43816 
(ΔmanC) and NTUH-K2044 (Δwzc), and confirmed that the capsule mutants 
exhibited reduced exclusion of nigrosin staining (Figure 4).  Both J774A.1 and 
RAW264.7 monolayers were challenged with K. pneumoniae strains at an MOI of 
10, and internalized bacteria were detected using a gentamicin protection assay.  
In both J774A.1 and RAW264.7 cells, the MGH 78578 strain was phagocytosed 
more efficiently than the ATCC 43816 and NTUH-K2044 strains (P<0.001) 
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(Figure 4).  This suggests that the K52 serotype capsule of the MGH 78578 
strain does not resist uptake by murine macrophages to the same degree as 
representative K1 and K2 serotype strains.  In addition, ATCC 43816 was 
phagocytosed more efficiently than NTUH-K2044 in both cell lines (P<0.001), 
suggesting that there may be differences in the antiphagocytic properties of K1 
and K2 capsular polysaccharides or other surface exposed factors.   
We therefore also investigated whether capsule alone mediates the 
antiphagocytic phenotype by comparing ATCC 43816 and NTUH-K2044 capsule 
mutants to relatively highly phagocytosed MGH 78578.  Both ATCC ΔmanC and 
NTUH Δwzc capsule mutants were phagocytosed at significantly higher rates 
than their isogenic wild type parent strains in both cell lines (Figure 5), and 
furthermore, the NTUH Δwzc was significantly less phagocytosed than the MGH 
78578 strain.  These data demonstrate that the NTUH Δwzc capsule mutant 
retains antiphagocytic properties which are distinct from capsular polysaccharide, 
suggesting that additional factors additionally mediate the antiphagocytic 
phenotype of K. pneumoniae.  The ATCC ΔmanC was phagocytosed at levels 
similar to the MGH 78578 K52 strain, and it is therefore not possible to conclude 
whether ATCC 43816 possesses non-capsule antiphagocytic determinants using 
the K52 MGH 78578 strain which may itself be antiphagocytic.  Due to the 
intrinsic antibiotic resistance of the MGH 78578 strain to common antibiotic 
markers used for molecular biology, we were unable to generate an acapsular 
MGH 78578 strain for these studies. 
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We decided to investigate whether K. pneumoniae is replication-
competent within cultured macrophages after internalization.  Both RAW264.7 
and J774A.1 murine macrophages were infected at an MOI of 10 with 
subsequent evaluation of bacterial colonization at time points 3, 4.5, 6, 9 and 12 
hr post infection.  As observed previously, MGH 78578 was internalized at the 
highest levels in both cell lines, while NTUH-K2044 had the lowest level of 
internalization at the 3 hr time point (Figure 6).  Proliferation of K. pneumoniae 
was observed for all bacterial strains, however during 9 hr of observation 
between the 3 and 12 hr time points the average fold increase in bacterial 
number was just 3.0-4.6 fold in J774A.1 cells.  Higher rates of proliferation were 
observed for ATCC 43816 and MGH 78578 in RAW264.7 cells, however NTUH-
K2044 saw only a 2.9 fold increase in bacterial numbers from 3 hr to 12 hr.  
These data indicate that the K1 (NTUH-K2044) and K2 (ATCC 43816) strains of 
K. pneumoniae are internalized at relatively low rates but are replication 
competent in cultured macrophages.  However, the K52 strain, MGH 78578, was 
phagocytosed at relatively high levels in both cell lines, and proliferated 
significantly in RAW264.7 cells.  Importantly, intracellular ATCC 43816 and MGH 
78578 exhibited significant outgrowth in cultured macrophages between the 3 
and 12 hr time points (both J774A. 1 and RAW264.7, P<0.001), indicating that K. 
pneumoniae possesses replicative viability within macrophages, in spite of its 
classification as an extracellular pathogen.  These data suggest that differences 
between K. pneumoniae serotype, and potentially other genetic determinants, 
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could impact the preferred host niche during disease, including the propensity to 
persist within macrophages. 
 
3.2.4 Respiratory murine model of K. pneumoniae infection 
We decided to investigate the virulence potential of the three sequenced 
K. pneumoniae strains in a murine respiratory disease model.  Because K. 
pneumoniae is known to colonize the upper respiratory tract (URT) in mammals, 
we developed a novel infection model to deliver K. pneumoniae non-surgically 
into the lung of mice using intubation-mediated intratracheal (IMIT) instillation, 
specifically modeling lower respiratory tract (LRT) disease.  Female BALB/c mice 
were challenged with one of the three K. pneumoniae study strains using the 
IMIT infection method using multiple challenge doses to estimate the 50% lethal 
dose (LD50).  Both ATCC 43816 and NTUH-K2044 were found to be highly 
virulent strains of K. pneumoniae (LD50 <100) while the MGH 78578 strain is 
significantly less virulent, with an LD50 >105.4 fold higher than the virulent strains 
(Table 3).  K. pneumoniae respiratory disease in the IMIT mouse model is 
associated with an acute course of disease with minimally lethal doses resulting 
in moribund disease within 3-4 days (Figure 7). 
Groups of mice infected with minimally lethal doses of ATCC 43816 and 
NTUH-K2044 (102.2 CFU) were necropsied to investigate bacterial burdens in 
host tissues.  Bacteria were enumerated by plate count from blood, and 
homogenates of lung, liver, and spleen.  Moribund mice were found to have the 
highest levels of host colonization in both blood and lung, followed by liver and 
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spleen (Figure 8).  One-way ANOVA with Tukey Post Test revealed no significant 
difference between ATCC 43816 and NTUH-K2044 bacterial burdens in any of 
the host samples examined.  These data reveal that both ATCC 43816 and 
NTUH-K2044 K. pneumoniae pneumonia is associated with development of a 
significant bacteremia and systemic spread to multiple organs.   
 
3.3 Discussion 
K. pneumoniae respiratory infections may result from several mechanisms 
of pathogen introduction into susceptible hosts including inhalation of 
environmental sources of bacteria, as it relates to community acquired 
pneumonia (CAP), or nosocomial foreign body introduction of K. pneumoniae into 
the respiratory system, as in ventilator associated pneumonia (VAP).  Thus, 
respiratory infections with K. pneumoniae are clinically important both to 
nosocomial pneumonia in hospital settings as well as CAP in developing areas of 
the world.  The primary focus of this work was to gain insight into the molecular 
mechanisms which contribute to the respiratory disease caused by virulent K. 
pneumoniae.  We therefore sequenced one of the commonly researched strains, 
capable of causing pneumonia in surrogate animal models.  The ATCC 43816 
strain was successfully sequenced by Next Generation approaches at 
approximately 80% coverage, based on estimated total sequence data relative to 
the NTUH-K2044 genome size.  The majority of ATCC 43816 sequence (>96%) 
was well conserved to both the highly virulent NTUH-K2044 and the minimally 
virulent MGH78578 strains suggesting that K. pneumoniae strains may have 
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large core genomes, and that key differences in virulence potential may be 
related to a small number of pathogenicity islands.   
Based on the data from our murine respiratory disease model, we 
identified NTUH-K2044 and ATCC 43816 as highly virulent K. pneumoniae 
strains, and MGH 78578 as a low virulence strain.  These findings are consistent 
with clinical evidence that K1 and K2 serotypes of K. pneumoniae are most 
commonly associated with severe disease presentations, including CAP, invasive 
presentations, as well as lethality in a mouse intravenous challenge model [192, 
213].  To the best of our knowledge, this current study provides the first 
experimental evidence demonstrating that a representative K52 clinical isolate is 
relatively avirulent in a murine respiratory disease model.  Thus, phenotypic 
evidence links the newly sequenced ATCC 43816 strain to the fully sequenced 
NTUH-K2044 rather than MGH 78578 strain.  The genetic systems found to be 
shared between NTUH-K2044 and ATCC 43816, but absent from MGH 78578 
included iron acquisition genes (yersiniabactin biosynthesis and iron transport), a 
Type 4 secretion system (T4SS), a CRISPR locus, and an acetonin catabolism 
locus.  Yersiniabactin biosynthetic operon has been previously demonstrated to 
be important to the function of ATCC 43816 in a murine intranasal respiratory 
disease model [92, 159], where yersiniabactin is thought to contribute to evasion 
of the activity of lipocalin2 in the lung – a host factor which neutralizes 
enterobactin-based iron acquisition [114].  The T4SS present in the virulent 
ATCC 43816 and NTUH-K2044 strains has been proposed to potentially 
represent a DNA conjugation system, and is also present in the related K. 
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variicola environmental isolate strain 342 [214, 215], thus future studies will be 
required to investigate the virulence potential of this secretion system in K. 
pneumoniae.  This study supports previous findings that the capsular serotype 
and the presence of the yersiniabactin iron acquisition systems contribute 
significantly to the disease potential of highly virulent K. pneumoniae strains, with 
the additional possibility that T4SS or acetonin catabolism may be important for 
K. pneumoniae disease.   
In this study, we investigated whether there were any significant 
differences in the ability of K. pneumoniae strains to persist within cultured 
macrophages.  K. pneumoniae is considered to be primarily an extracellular 
pathogen, although there is evidence that this organism may be internalized in 
human epithelial cell lines [216, 217].  Furthermore, K. pneumoniae can be taken 
up into cultured murine peritoneal macrophages, and are also internalized in vivo 
in alveolar macrophages [95].  However, capsular polysaccharide may mediate 
blocking the initial attachment of bacteria to cells, reducing internalization [218].  
Given the importance of capsule in mediating the uptake of K. pneumoniae into 
phagocytic cells, we anticipated that the representative K2 strain in our study, 
ATCC 43816, may resist uptake into cultured macrophages given the previous 
discovery that the K2 serotype is associated with an absence of mannose 
residues in the capsular polysaccharide [139].  Similarly, the gmd and wcaG 
genes, present in K1 serotype capsular loci, are required for the modification of 
mannose to fucose, and a corresponding low level of mannose/high level fucose 
in K. pneumoniae isolates which possess these genes [219].  We had observed 
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that the K1 strain NTUH-K2044 exhibited particularly low uptake into cultured 
murine macrophages in our studies, and that the K2 strain ATCC 43816 also had 
a lower level of uptake than the K52 strain MGH78578.  Similarly, capsule has 
been demonstrated to mediate anti-phagocytosis in both amoeba and alveolar 
macrophages, suggesting that this role for capsule is ubiquitously important 
across a range of host-pathogen interactions with professional phagocytes [203, 
220]. Given the potential role of the mannose receptor in facilitating 
phagocytosis, and the reduced level of mannose residues in K1 and K2 serotype 
capsules, it is possible that modulation of the polysaccharide surface of K. 
pneumoniae may represent an important strategy for evading host defense.   
Consistent with prior studies, we found that acapsular K. pneumoniae 
mutants also exhibited increased uptake into macrophages, however, we also 
observed that the increase in uptake of the NTUH-K2044 capsule mutant did not 
achieve the level of uptake of the representative K52 serotype strain.  This 
finding suggests that the NTUH-K2044 strain possesses additional non-capsule 
antiphagocytic factors, or that the MGH78578 strain actively promotes its uptake 
into macrophages.  Given that K. pneumoniae capsule does possess 
antiphagocytic properties as a strategy to act primarily as an extracellular 
pathogen, we hypothesize that the K52 MGH 78578 strain does not promote its 
own uptake, and instead, we hypothesize that the function of K52 capsules would 
be as an antiphagocytic determinant consistent with other serotype capsules.  
Thus, we interpret that the NTUH-K2044 strain possesses multiple mechanisms 
to resist phagocytosis, which is consistent with previous findings that capsule, 
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LPS, carnitine metabolism, and the ClpX protease are all required to resist entry 
into amoeba and human neutrophils [220].  We conclude that K. pneumoniae 
antiphagocytosis is mediated by a multifactorial process and that capsule alone 
is insufficient to account for this phenotype.  This conclusion is consistent with 
prior published findings that additional genetic loci participate in mediating K. 
pneumoniae antiphagocytosis, including genes for LPS, the ClpX protease, and 
carnitine metabolism [220]. 
In our respiratory challenge studies, the K1 and K2 serotype strains 
possessed a significantly higher virulence in mice than the K52 serotype strain, 
supporting the possibility that evasion of phagocytosis is a strategy employed by 
K. pneumoniae to enhance virulence in mammalian hosts.  Thus, these finding 
support the characterization of K. pneumoniae as an extracellular pathogen, 
whereby the most virulent strains are also the most antiphagocytic.  These 
results are consistent with previous reports which have demonstrated that 
antiphagocytic properties of K. pneumoniae capsule are associated with highly 
virulent K1 and K2 serotypes in panels of Asian strain isolates [131, 140].  It is 
however noteworthy that several additional virulence-associated genetic 
determinants are common to the K1 and K2 representative strains investigated in 
this study, including mechanisms of iron acquisition, highlighting that K. 
pneumoniae serotype is not the sole distinguishing factor for predicting disease 
potential in mammalian hosts.   
Our data supports a link between evasion of phagocytosis and virulence 
potential as an interpretation that K. pneumoniae is primarily an extracellular 
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pathogen.  However, we interestingly demonstrate that K. pneumoniae strains 
are fit to replicate within macrophages once internalized.  This is an intriguing 
finding that may suggest that a subpopulation of K. pneumoniae may use an 
intracellular lifestyle as part of the disease process.  Future studies will be 
required to characterize to what extent K. pneumoniae has adapted to 
intracellular host-pathogen interaction, and what role the intracellular lifestyle 
might play in vivo. 
We developed a novel respiratory disease model to study K. pneumoniae 
pneumonia which facilitated an investigation of the lower respiratory tract (LRT) 
colonization in the absence of the involvement of other primary sites of infection.  
Our motivation to develop this model system was in part shaped by our 
observations that bacterial pathogens may opportunistically infect the upper 
respiratory tract (URT) in a process which is unique from that observed during 
human disease [221].  Direct non-surgical instillation directly into the LRT also 
directly mimics a normal route of nosocomial acquisition of K. pneumoniae 
associated with VAP.  Our novel intubation-mediated intratracheal (IMIT) delivery 
of bacteria facilitates: i) the use of a flow meter to validate the placement of a 
catheter into the trachea, ii) the ability to instill bacteria directly into the lung via a 
blunt needle inserted through the catheter lumen, iii) delivery of bacteria into the 
lower lobes of the lung under positive pressure, and iv) minimal trauma to the 
host owing to the non-surgical nature of the procedure.   
We found that our novel IMIT infection model lowered previously reported 
LD50 values for both i.n. and surgical i.t. infection models, suggesting that 
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targeted delivery of a reduced number of bacteria to the lungs enhances the 
disease potential of K. pneumoniae.  The LD50 for the ATCC 43816 strain in the 
IMIT model is 101.8 – 102.8 fold less than previously published LD50 values using 
intranasal models [92, 222], suggesting that the IMIT model provides a lower 
LD50 due to the ability of the intubation tubing to briefly occlude the air space, 
allowing for positive pressure delivery of organisms deep into the lung, rather 
than passive delivery into the lung in shallowly breathing anesthetized animals.  
Thus, our IMIT model improves the disease potential of K. pneumoniae in lung-
specific disease, and may be an excellent instillation method for therapeutic and 
diagnostic reagents in studies requiring LRT delivery.  
In summary, our study has provided a first draft sequence of the ATCC 
43816 genome which will support future investigations of K. pneumoniae 
function.  We also have provided the first description of the growth potential of K. 
pneumoniae in cultured murine macrophages, supporting a growing body of 
evidence that K. pneumoniae may not be exclusively an extracellular pathogen.  
Finally, we have developed and employed a novel non-surgical, lung-specific 
infection model which allows for targeted low dose inoculation of K. pneumoniae 
giving rise to a lethal pneumonia in mice, and revealing a significant difference in 
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Table 2. Genetic elements common/unique to sequenced strains 
Genetic loci common to NTUH-
K2044 
Genes mapped (KP1_) 
Yersiniabactin biosynthesis 3583-3586, 3588-3593, 3605-3609, 
3611-3613 
Type IV Secretion 3634, 3638-3641, 3643 
Iron transport 1980-1989 
CRISPR locus 3164-3166, 3171 
Acetonin catabolism 1112-1121 
Conserved and hypothetical genes 2362-2364, 2378-2385, 3239-3240, 
3773 
  
Genetic loci common to MGH 
78578 
Genes mapped (KPN_) 
Metabolic  00033-00034, 00594-00598, 03359-
03370, 03372, 04612-04613 
Conserved and hypothetical genes 01146-01148, 01151-01164, 01432-
01433,  01316-01317, 04518 
  
ATCC 43816 genetic loci absent 
from NTUH-K2044 and MGH 78578  
Genes 
Escherichia coli UMN026-like 
bacteriophage 
ECUMN_0964-0965, 0975, 0977-0986, 
0994-0996 
Klebsiella pneumoniae subsp.  
rhinoscleromatis ATCC 13884-like 
bacteriophage 
HMPREF0484_4775, 4777-4779, 1182 
Enterobacter radicincitans DSM 
16656 acriflavine resistance 
Y71_5381-5385 
Klebsiella oxytoca 10-5243 fimbrial 
biosynthesis 
HMPREF9687_02419-02420 
Hypothetical protein Salmonella 
enterica subsp. enterica serovar 
Saintpaul str. SARA29 
SeSPB_A4698 
Hypothetical protein Enterobacter 
hormaechei ATCC 49162 
HMPREF9086_3347 
Hypothetical protein Klebsiella sp. 
4_1_44FAA 
HMPREF1024_04074 
Hypothetical protein Escherichia 
hermannii NBRC 105704 
EH105704_01_06400 
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Table 3. Probit analysis of IMIT-infections of BALB/c mouse using K. 
pneumoniae strains 
Strain LD50 (95% CI*) 
ATCC 43816 4.71x101 (1.36x101-1.63x102) 
NTUH-K2044 2.33x101 (5.4x100-1.01x102) 
MGH 78578 1.37x107 (9.50x106-1.97x107) 
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Figure 2. Alignment of the ATCC 43816 sequence to previously sequenced 
K. pneumoniae chromosomes. Next generation sequencing of ATCC 43816 
produced 1763 contigs which were aligned to published NTUH-K2044 (Panel A) 
and MGH 78578 (Panel B) chromosomes. The locations of the contigs are shown 
as long green lines. The two outer tracks depict the annotated genes in the 
reference genomes (on both strands) while the two inner tracks show GC content 
and GC skew, respectively which strongly effects sequencing as can be seen 






















Figure 3. Genetic organization of the ATCC 43816 K2 capsule locus.  Scale representation of the capsular 
polysaccharide biosynthetic locus (galF-uge) and LPS locus (wzm-yvet).  The central domain of the capsule locus 
(orf7-orf13) represents the antigenic diversity region unique to K2 serotype capsules, while the remainder of the 
locus is well conserved with other K. pneumoniae capsule loci. 
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Figure 4. Negative staining of capsular polysaccharide from ATCC 43816 
and NTUH-K2044 strains. Overnight bacterial suspensions of ATCC 43816 (A), 
ATCC ΔmanC (B), NTUH-K2044 (C) and NTUH Δwzc (D) were mixed in 1:1 ratio 
with 10% nigrosin. The loss of the capsular polysaccharide from the mutant 
strains was illustrated by the decrease exclusion of the nigrosin dye which was 
visualized with Zeiss Axio microscope (63x magnification). Imaris analysis 
identified that the cross-sectional areas of ATCC ΔmanC, and NTUH Δwzc 
mutants were reduced by 36.21%, and 28.59%, relative to their isogenic parents.   
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Figure 5. Uptake of K. pneumoniae wild type and capsular polysaccharide 
mutants strains into cultured murine macrophages. K. pneumoniae strains 
ATCC 43816 (K2), NTUH-K2044 (K1) and MGH 78578 (K52) or capsule mutants 
ATCC ΔmanC, and NTUH Δwzc were incubated in the presence of cultured 
murine macrophage cell lines J774A.1 or RAW264.7 at an MOI of 10 in 96 well 
plates.  At one hour post-infection, gentamicin was introduced to eradicate 
extracellular bacteria, and uptake of K. pneumoniae strains into macrophages 
was assessed at 3 hr post-infection by plate counting.  Triplicate samples were 
enumerated and data analyzed as a percentage of the inoculum, with the results 
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Figure 6. Growth potential of K. pneumoniae strains in cultured murine 
macrophages. K. pneumoniae strains ATCC 43816 (K2), NTUH-K2044 (K1) and 
MGH 78578 (K52) were incubated in the presence of cultured murine 
macrophage cell lines J774A.1 or RAW264.7 at an MOI of 10 in 96 well plates.  
At one hour post-infection, gentamicin was introduced to eradicate extracellular 
bacteria.  At 3, 4.5, 6, 9, and 12 hr post-infection, a triplicate set of samples was 
processed for enumeration of intracellular bacteria.  The data is representative of 

















Figure 7. Survival analysis of K. pneumoniae respiratory challenge. Groups of five female BALB/c mice were 
challenged with K. pneumoniae strains ATCC 43816 (K2), NTUH-K2044 (K1) or MGH 78578 (K52) by IMIT 
respiratory infection.  Mice were monitored for 14 days, and moribund mice were euthanized.  The challenge dose 
for each survival curve group is indicated. 
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Figure 8. Bacterial burden of K. pneumoniae-infected mice. Groups of five 
female BALB/c mice were infected with K. pneumoniae strains ATCC 43816 or 
NTUH-K2044 and tissues were harvested at the onset of moribund disease, and 
homogenized in 1ml of PBS.  Bacteria were enumerated from blood and from 
homogenates of lung, liver, and spleen.  The results present a min/max box and 
whisker plot for each infected tissue (n=5).  Statistical analysis was carried out by 










DIRECT MONITORING OF MEROPENEM THERAPEUTIC EFFICACY 
AGAINST KLEBSIELLA PNEUMONIAE RESPIRATORY INFECTION USING 
OPTICAL DIAGNOSTIC IMAGING 
 
4.1 Introduction 
Klebsiella pneumoniae ssp. pneumoniae (K. pneumoniae) is a Gram-
negative bacteria (GNB) ubiquitously present in the environment, and can also 
be cultured from host mucosal surfaces, and medical devices, where it excels as 
a nosocomial pathogen [14, 188, 223]. As an opportunistic pathogen, K. 
pneumoniae causes community and hospital acquired infections with more cases 
being isolated from the latter. K. pneumoniae is a causative agent for multiple 
nosocomial diseases including urinary tract infection, septicemia, pneumonia, 
and premature infant infections in the intensive care unit [224-228]. K. 
pneumoniae is a significant contributor to hospital acquired pneumonia 
accounting for 25-43% of Gram-negative nosocomial respiratory infections [229]. 
The pneumonic disease is characterized by a rapid progressive clinical course 
leading to multilobar involvement, abscess formation, and systemic spread of the 
bacteria with severe outcomes leaving little time for therapeutic intervention [95, 
230-233]. Populations at higher risk of acquiring the respiratory disease include 
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neonates, immunocompromised individuals, and people with underlying diseases 
[35, 234, 235]. The mortality rates associated with the pneumonic disease are 
quite high approaching or exceeding 50% even with antibiotic treatment [80, 236, 
237].  
There is a growing concern about the emergence of multidrug resistant 
(MDR) K. pneumoniae strains such as the extended-spectrum beta-lactamases 
(ESBLs) and more recently the carbapenem resistant Klebsiella (KPC) which 
limit the treatment options with the current available therapeutics [238-242]. 
Therefore, there is an urgent need for the development of new antimicrobial 
agents to treat infections caused by this critical pathogen. In developing novel 
drugs, many therapeutic studies focus on monitoring host biometric 
endpoint/disease resolution criteria such as weight, temperature, and symptoms 
of disease to indirectly monitor therapeutic efficacy, while neglecting the direct 
effect of the drug on the pathogen itself. Therefore, to address this scientific gap 
we decided to generate a bioluminescent K. pneumoniae bioreporter strain in 
order to monitor noninvasively therapeutic efficacy in vivo while focusing our 
attention on microbial viability in real-time instead of inferring the drug efficacy 
from host physiology.  
Bioluminescence imaging (BLI), an approach developed over the past 
decade, has been used to detect bioluminescent live cells within small animals 
[243]. The BLI involves the use of luminescent microorganisms to infect a host 
and monitor disease development using optical diagnostic imaging, and bacteria 
that do not naturally produce bioluminescence can be engineered to do so 
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through inserting a luxCDABE operon into bacterial genome or by transforming 
the bacteria with a plasmid carrying the lux genes [244]. The lux operon encodes 
for the elements needed to generate a luciferase enzyme together with its 
substrate. In the presence of oxygen, luciferase catalyzes the breakdown of the 
substrate producing blue-green light as a byproduct [245]. BLI has been 
employed by different groups to study altered disease outcomes upon infecting 
animals with bacterial mutants [221, 246-248], to examine the change in 
dissemination patterns upon introducing the microbes through different routes of 
infection [246, 247], and to test antimicrobial agents efficacy in vivo [249-253]. 
There are multiple advantages for the use of BLI in biomedical research which 
include: 1) minimizing the number of animals needed to perform time course 
studies by eliminating the need to sacrifice animals at specific time points to 
enumerate tissue burdens, 2) eradicating the requirement for additional steps to 
estimate bacterial numbers in broth media or within host tissues reducing 
processing time and cost, 3) reducing individual-to-individual variations since 
bacterial viability is monitored within the same group of animals over the entire 
course of disease reducing error and increasing resolution, and 4) identifying 
microbial dissemination to unexpected host niches.  
As one of the broad spectrum carbapenem antibiotics, meropenem has 
been demonstrated to be effective in treating patients with nosocomial 
pneumonia [254-256]. Meropenem is active against most clinically important 
Gram-negative pathogens of the lower respiratory tract including MDR 
Enterobacteriaceae [257-261].  Unlike imipenem, another drug from the 
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carbapenem family, meropenem is more resistant to hydrolysis by the renal 
dehydropeptidase I (DHP-I), and therefore, meropenem does not require the 
additional administration of the DHP-I inhibitor cilastatin [262, 263]. Meropenem 
is effective in penetrating respiratory tract tissues [264], making it a good drug for 
treating infections at that anatomical site. It is the recommended drug for treating 
pulmonary infections caused by K. pneumoniae especially for the MDR isolates 
[43, 265]. 
 Meropenem was demonstrated to be effective against K. pneumoniae 
infections in mice including respiratory, blood, and thigh infections but with no 
calculation of the drug 50% effective dose (ED50) [87, 118, 266, 267]. In those 
studies meropenem was used to treat MDR K. pneumoniae strains which 
typically require high bacterial inoculums in order to cause a respiratory infection 
in animals [87, 118]. On the other hand, we have demonstrated that K. 
pneumoniae ATCC 43816 strain is capable of causing lethal pulmonary disease 
with a very low dose of the bacteria [99]. ATCC 43816 strain has also been used 
frequently in biomedical science investigations directed toward characterizing 
host response to the pulmonary disease [111, 113, 115]. In addition, we 
demonstrated that this strain is amenable to genetic manipulation [99], which 
makes it an excellent model pathogen suitable for conducing therapeutic studies 
against K. pneumoniae respiratory disease. 
We decided to generate a bioluminescent reporter strain from ATCC 
43816 to enable noninvasive monitoring of therapeutic efficacy of current 
clinically important drugs and future novel treatment approaches against K. 
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pneumoniae respiratory disease. Furthermore, our knowledge about K. 
pneumoniae pathogenesis, virulence factors required during the respiratory 
disease and host-pathogen interaction is limited, and therefore, we decided to 
use the bioluminescent strain to facilitate such studies. The bioluminescent strain 
was utilized for direct monitoring of the viability of a manC capsule mutant, 
known to be attenuated during the pulmonary disease [92], to investigate 
whether BLI would enable monitoring the initiation of bacterial clearance from the 
lung. Finally, we have demonstrated previously that K. pneumoniae is capable of 
intracellular proliferation within host cells [99], and thus, the bioluminescent K. 
pneumoniae strain was employed to noninvasively monitor this intriguing 
phenotype to facilitate future investigations directed toward characterizing the 




4.2.1 Generation of bioluminescent K. pneumoniae bioreporter strain 
To begin to address the development of biodiagnostic imaging capability 
to monitor the therapeutic efficacy in vivo, we started by generating a 
bioluminescent strain. The bioluminescent K. pneumoniae strain (named 
JSKP001) was generated through the insertion of the luxCDABE operon into the 
chromosome of the strain ATCC 43816, commonly used to study host response 
to lung infection [111, 113, 115]. The lux operon was engineered to be under the 
control of the 50s ribosomal subunit rplU promoter expected to be constitutively 
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expressed in viable bacteria due to the requirement for protein synthesis in 
metabolically active microbes. The insertion of the lux operon took place between 
the convergently transcribed fusA and yeeF genes which represent an insertional 
target for the nitrogen fixation operon of related Klebsiella spp., and therefore, 
the insertion in this site is predicted not to impact other genetic systems. 
However, the lux system requires energy from the cell which might impact 
bacterial growth potential.  
To confirm that the insertion of the lux operon did not alter bacterial 
fitness, we tested the ability of the JSKP001 strain to proliferate in broth culture 
media relative to its parental strain. Overnight bacterial cultures in LB broth were 
diluted 1,000 fold and bacterial growth was monitored for 4 h by OD600 and 
bioluminescence. The JSKP001 had a doubling time similar to the ATCC 
parental strain, (estimated between 60 – 200 min) of 20.83±0.49 and 21.73±0.48 
min, respectively, which demonstrates that the knock-in mutagenesis did not 
affect the bacterial fitness in vitro (Figure 9A).  
Further, to investigate the correlation between bacterial numbers and 
bioluminescence, overnight bacterial cultures were diluted 1,000 fold and grown 
in LB broth at 37oC with agitation for 3 hr, where bioluminescence and bacterial 
numbers were estimated at 30 min intervals. We had excellent correlation (R2 = 
0.971) between bioluminescence and bacterial numbers (Figure 9B). Together, 
these data demonstrate that bioluminescence can be used to estimate bacterial 
numbers in broth culture media; the insertion of the lux operon into ATCC 43816 
genome did not impact bacterial fitness.   
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4.2.2 Noninvasive tracking of respiratory disease  
We demonstrated that the lux operon acquisition of energy does not 
impact the ability of K. pneumoniae to grow in broth culture. However, this is an 
ideal and artificial situation where the bacteria is being provided with a rich 
source of nutrients; therefore, we decided to investigate if the insertion of the lux 
operon affected bacterial fitness in vivo where nutrients/energy availability is 
more limited. The ability of JSKP001 and ATCC 43816 strains to cause the 
pulmonary infection were compared where albino C57BL/6J mice were infected 
with lethal dose (~ 104.9 CFU) with either of the two bacterial strains using 
intubation-mediated intratracheal (IMIT) installation to enhance lung-specific 
delivery of pathogen [99, 187]. Animals were euthanized upon meeting endpoint 
criteria consist of heart rate of 400 beat per minute (bpm) or below in addition to 
demonstration of clear signs of illness including reduced mobility, decreased 
resistance upon handling, hunching, and shortness of breath (SOB). Infection 
with both ATCC 43816 and JSKP001 resulted in the development of the acute 
respiratory infection with no significant difference (p = 0.26) in the ability to cause 
a lethal moribund disease with median time to death (MTTD) of ~3 days (Figure 
10A). This means that in addition to the demonstration that in vitro fitness of 
JSKP001 was not impacted by the insertion of the lux operon; the ability of the 
bacteria to cause lethal pulmonary infection was not altered as well.  
We next decided to investigate the ability of the JSPK001 for systemic 
dissemination in comparison to its parental strain as a higher resolution approach 
 
   82 
 
of characterizing the impact of the insertion of the lux operon on the fitness of the 
bioluminescent strain. We looked at bacterial burdens in blood, BAL, lung, liver, 
spleen, and kidneys collected from animals at moribund disease. We observed 
similar bacterial burdens in the tissues collected from animals infected with 
JSKP001 and ATCC 43816 strains (Figure 10B). Collectively, we demonstrated 
that the insertion of the lux operon did not alter the virulence of the 
bioluminescent strain in our mouse lung-specific disease model and that 
JSKP001 is capable of disseminating and colonizing other tissues to wild type 
levels.   
To have a better understanding of the virulence of JSKP001 and to 
facilitate future studies, we investigated the 50% lethal dose (LD50) for 
bioluminescent strain in the mice. Animals were infected with 102 – 104.9 CFU 
using IMIT, monitored for the development of the respiratory disease, and 
euthanized when moribund. The highest bacterial inoculum (104.9 CFU) caused 
100% mortality while all animals survived the 102 CFU challenge (Figure 11). 
Using probit analysis, the JSKP001 LD50 was calculated to be 102.8 CFU making 
the albino C57BL/6J mouse model more resistant to the respiratory disease than 
BALB/c mice used in previous work [99]. 
We next investigated whether diagnostic imaging could be used to 
noninvasively monitor K. pneumoniae colonization of host lungs. Mice were 
infected with 125x the LD50 of the JSKP001 strain (104.9 CFU) and bacterial 
colonization of host lungs as a function of bioluminescence were monitored twice 
daily using optical diagnostic imaging. Bioluminescence imaging (BLI) enabled 
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real-time monitoring of bacterial colonization of mice lungs as well as bacterial 
dissemination to other anatomical sites (Figure 12A). Bioluminescence was 
detectable within mice thoracic cavity as early as 18 hr post-infection and kept 
increasing throughout the time course of the disease (Figure 12B). Interestingly, 
even though the animals were infected with almost the exact amount of bacterial 
inoculum, knowing how effective IMIT is as a lung-specific delivery system [187], 
we observed ~1.3 log variation in thoracic cavity bioluminescence from the 
different animals (Figure 12B). Moreover, higher bacterial burdens at the 18 hr 
time point correlated with earlier development of moribund disease with R2 of 
0.68 (Figure 12C). The variation in bioluminescence could be due to differences 
in light expression, and therefore, it is important to investigate whether 
bioluminescence correlate with bacterial numbers in vivo as we have 
demonstrated in broth media. Other explanations of such phenomena is that in 
some animals the bacteria might be going under early dissemination as observed 
in figure 12A, and thus, those animals end up with less bacteria in the lung. 
Another possibility might involve early eradication of bacteria by host immune 
system which is taking place in some animals but not others.  
 Together, we demonstrated that the genetic manipulation performed on 
the JSKP001 strain did not impact bacterial fitness in broth media and in vivo. 
We determined the LD50 for the JSKP001 strain and demonstrated that albino 
C57BL/6J mice are less susceptible to the respiratory disease than the 
previously used BALB/c model [99]. BLI allowed for noninvasive monitoring of the 
development of the respiratory disease in mice and revealed some possible 
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interesting host-pathogen interactions. Finally, we have provided evidence that 
optical diagnostic imaging can facilitate earlier prediction of disease outcomes. 
 
4.2.3 Bioluminescence correlates with bacterial burdens  
To investigate the differences observed in thoracic cavity bioluminescence 
at early time point, we decided to test whether bioluminescence represent 
bacterial numbers within host tissues. Albino C57BL/6J mice were infected with 
JSKP001 (103 – 105.2 CFU), monitored for the development of the respiratory 
disease, euthanized when moribund, and blood, BAL, lung, liver, spleen, and 
kidneys were collected for ex vivo bioluminescence measurement, and bacterial 
enumeration. Similar to the previous in vitro data, we had good correlations 
between bacterial numbers and bioluminescence where the R2 values for blood, 
BAL, lung, liver, spleen, and kidneys were 0.69, 0.47, 0.57, 0.81, 0.53, and 0.8, 
respectively (Figure 13A-F).  
Furthermore, we examined if bioluminescence can estimate the level of 
bacterial colonization within host thoracic cavity in life. Bioluminescence 
estimated at moribund disease right before euthanasia was compared with 
bacterial burdens in lung homogenates. Similarly, we had good correlation 
between the two measurements with an R2 value of 0.55 (Figure 13G). These 
outcomes demonstrate that bioluminescence can be utilized to noninvasively 
estimate bacterial loads within host tissues. Together with the in vitro data, we 
demonstrated that the lux operon, under the control of the rplU promoter, is being 
constitutively expressed in broth media as well as within host tissues. 
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Furthermore, we have demonstrated that the 1.3 log variation in bioluminescence 
observed from mice lungs at the 18 hr time point (Figure 12B) was not due to 
differences in light expression but rather it might be due to differences in early 
bacterial trafficking or early clearance by host immune response.  
 
4.2.4 In vitro monitoring of bacterial viability using bioluminescence  
One benefit of having a bioluminescent K. pneumoniae strain is to enable 
the performance of high throughput in vitro assays for testing the efficacy of 
antimicrobial agents against this important pathogen.  MicroChem-Plus is a 
quaternary multipurpose common detergent disinfectant designed for controlling 
the hazard of cross contamination of microbial pathogens, and it is broadly used 
in many facilities including hospitals and nursing homes. It is one of many 
antimicrobial agents and we decided to use this strong disinfectant to investigate 
whether bioluminescence can facilitate tracking bacterial viability over a short 
time course upon initiating the detergent treatment.  
LB broth culture of exponentially growing JSKP001 strain were 
centrifuged, resuspended in PBS, and treated with serially diluted MicroChem-
Plus disinfectant where bacterial viability were monitored at room temperature by 
measuring bioluminescence at 1 min intervals and bacterial numbers were 
estimated following 11 min of incubation. Rapid drop in bioluminescence was 
observed within minutes after treatment initiation and CFU numbers estimated at 
11 min were consistent with light emitted at that time point suggesting that the 
decrease in bioluminescence observed at earlier time points represent loss of 
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bacterial viability (Figure 14A, and B). Slight decrease in bioluminescence was 
observed in the control group (0% MicroChem-Plus) which is probably due 
alteration in lux transcription levels caused by transferring the bacteria from rich 
broth (LB) into PBS. The use of MicroChem-Plus at the 2% manufacturer 
recommended concentration was able to kill the bacteria in less than a minute 
which was illustrated by the diminished bioluminescence consistent with the fact 
that the emission of bioluminescence requires continuous supply of energy 
provided by living microorganisms.  
Furthermore, we have measured the correlation between bioluminescence 
and bacterial numbers at the 11 min time point, in sub-lethal concentrations of 
the disinfectant, and found out that the relationship between the two 
measurements are direct with R2 value of 0.99 (Figure 14C), demonstrating that 
the loss of bioluminescence represent loss of viability and the transition from loss 
of bacterial viability to loss of light seems to be immediate. These outcomes 
demonstrate the power of the bioluminescent bioreporter tool to allow 
noninvasive viability assessments which are typically not possible using standard 
bacteriological approaches.  
 
4.2.5 In vitro tracking of bacterial growth inhibition by meropenem  
Having demonstrated that bioluminescence is a direct measurement of 
bacterial viability, we next decided to investigate whether we can use 
bioluminescence to monitor the impact of clinically important antibiotics such as 
meropenem on bacterial growth in vitro. Similar to other beta-lactam antibiotics, 
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meropenem is bactericidal to many Gram-negative bacteria in which it inhibits 
bacterial cell wall synthesis. We utilized meropenem in a time course assay 
where an exponentially growing bacteria were mixed with serially diluted 
meropenem and bacterial growth was monitored by OD600 (Figure 15A) and 
bioluminescence (Figure 15B). Similar dose response of bacterial growth 
inhibition by the antibiotic was observed by both measurements (Figure 15A and 
15B).  
Furthermore, meropenem 50% effective concentration (EC50) calculated 8 
hr post treatment using bioluminescence (0.015 µg/ml) was not significantly 
different (p = 0.059) from the EC50 estimated by OD600 (0.023 µg/ml) (Figure 15C 
and 15D). Meropenem minimum inhibitory concentration (MIC) against JSK001 is 
estimated to be 0.125 µg/ml, rendering this strain sensitive to the antibiotic. 
Together, these data demonstrate that bioluminescence can be used to monitor 
bacterial viability upon treating the microbes with an antibiotic and can also 
facilitate estimating antibiotics EC50 alternative to the traditionally used OD600 
measurement, potentially with improved limit of detection.  
  
4.2.6 Noninvasive monitoring of meropenem therapeutic efficacy in mice 
Having demonstrated that using BLI we could monitor bacterial viability in 
vitro upon treating the microbes with antimicrobial agents, we decided to 
investigate if the same concept is applicable in vivo. We wanted to test whether 
we can use optical diagnostic imaging to monitor the efficacy of current and novel 
therapeutics noninvasively, and since we have demonstrated that the JSKP001 
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strain is sensitive to meropenem, we decided to utilize this antibiotic as a proof of 
concept to investigate this question. Meropenem is an important drug for treating 
K. pneumoniae infections including pneumonia [43, 87, 118, 265-267]. Therefore, 
we decided to investigate if meropenem is capable of resolving the respiratory 
disease and if the direct impact of the therapeutic on bacterial viability can be 
monitored in vivo using BLI.  
To develop a working understanding of the preferable meropenem 
concentration for conducting the in vivo monitoring, we have performed survival 
studies and identified meropenem ED50 in our lung-specific respiratory disease 
model. Albino C57BL/6J mice were infected intratracheally with a lethal dose of 
JSKP001 (104.9 CFU), treated subcutaneously with increasing concentrations of 
meropenem antibiotic q12h (96 – 400 mg/kg/day), and euthanized upon reaching 
moribund disease (described earlier) or after completing 7 days of monitoring. 
Full protection from the respiratory disease was achieved with the 400 mg/kg/day 
treatment, while less protection was observed the more we titrate the antibiotic 
(Figure 16A), and meropenem ED50 was estimated to be 221 mg/kg/day. 
 The development of the respiratory disease in the mice was monitored by 
measuring animals’ heart rates and thoracic cavity bioluminescence. Heart rate 
was used previously to monitor progression of a respiratory infection caused by 
another pathogen where bradycardia was associated with bad prognosis [268]. 
We decided to examine if heart rate would enable monitoring the progression of 
K. pneumoniae pulmonary disease in comparison to BLI. The highest dose of 
meropenem (400 mg/kg/day) was associated with very early eradication of the 
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bacteria where lung bioluminescence were below 3 standard deviation from 
background mean (Figure 16E). The increase in bacterial replication in the 
thoracic cavity monitored by bioluminescence coincided with decreased heart 
rate (Figure 16B – D and 16F – I). Interestingly, we observed that 
bioluminescence was able to detect the development of the respiratory disease 
by 15.71±3.672 hr (p = 0.0008) earlier than heart rate.  
Collectively, the bioluminescent JSKP001 strain allowed for noninvasive 
monitoring of the therapeutic efficacy of meropenem against K. pneumoniae 
respiratory infection. Similar to previous studies, we demonstrated that the 
development of the pulmonary disease is associated with bradycardia [268]. 
However, our data suggest that BLI allow for earlier prediction of disease 
outcomes relative to heart rate. We propose that the bioluminescent K. 
pneumoniae strain together with our lung-specific disease model might serve as 
an improved model for preclinical testing of innovative antimicrobial agents 
against the respiratory disease caused by this important pathogen. 
  
4.2.7 Tracking the clearance of manC mutant using optical diagnostic 
imaging  
We decided to investigate whether optical diagnostic imaging will facilitate 
a better understanding of K. pneumoniae pathogenesis by testing if the clearance 
of a manC capsule mutant, known to be attenuated in murine intranasal disease 
model [92], could be monitored using BLI. The manC gene (also known as cpsB) 
encode for mannose-1-phosphate guanylyl transferase which is involved in the 
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synthesis of GDP-D-mannose that gets converted into GDP-L-fucose, the 
precursor of fucose [269]. A manC mutant was generated in JSKP001 using 
allelic exchange mutagenesis creating the strain JSKP001ΔmanC. Albino 
C57BL/6J mice were infected with JSKP001 and JSKP001ΔmanC strains by 
IMIT using 104.1 and 108 bacterial inoculums, respectively. The 108 CFU 
represent the highest dose we instill using IMIT. Deleting the manC gene 
attenuated the ability of K. pneumoniae to cause the respiratory disease in our 
lung-specific disease model by >3.9 log relative to its parental strain (Figure 
17A), in which animals infected with the wild type strain demonstrated 80% 
mortality while 0% mortality was observed in mice infected with the 
JSKP001ΔmanC strain. Thoracic cavity bioluminescence of mice infected with 
the capsule mutant was below the limit of detection (LOD) as early as 18 hr post 
infection suggesting early clearance of the bacteria (Figure 17B). Bacterial 
burdens estimated from blood, BAL, lung, liver, spleen, and kidneys at 2 weeks 
post infection from mice inoculated with the manC mutant were less than 
bacterial numbers estimated for the same tissues collected from moribund 
animals infected by the parental strain (Figure 17C). For most tissues bacterial 
culture did not detect capsule mutant with the exception being the lung where 
there was low burden of ~3.52 logs at two weeks post infection. 
We next decided to investigate whether diagnostic imaging can be used to 
noninvasively monitor clearance of an attenuated mutant. We looked at the 
capsule mutant which we know to be attenuated at 108 CFU, and knowing that 
the bacteria is going to be undetectable by bioluminescence signal by 18 hr, we 
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started imaging the animals at earlier time points and euthanized them at 6.5 hr. 
Mice were infected with 108 CFU of the JSKP001ΔmanC strain and imaged at 
0.5, 3.5, and 6.5 hr post infection followed by euthanasia and lungs bacterial 
burdens estimation. Using thoracic cavity bioluminescence, we observed initial 
bacterial growth by 3.5 hr post infection in half of the animals, which was followed 
by a subsequent drop in bacterial numbers in all mice lungs at 6.5 hr suggesting 
initiation of clearance after 3.5 hr of infection (Figure 18A). The average bacterial 
load in mice lungs estimated at 6.5 hr post infection is ~7.83±0.31 log CFU which 
is ~0.2 log less than the inoculum (8 log) used to infect the animals again 
suggesting the initiation of clearance (Figure 18B). The amount of 
bioluminescence estimated from life animal at the 6.5 hr correlated very well with 
lungs bacterial numbers enumerated following euthanasia (Figure 18C) 
demonstrated bioluminescence is a direct measurement of bacterial numbers 
similar to previous observations (Figure 13), and that removing bacterial CPS did 
not impact the ability to monitor bacterial viability in vivo using BLI. Together, 
these data demonstrate that the manC mutant is attenuated in our IMIT infection 
model in consistence with previous findings demonstrating the attenuation of a 
manC (or cpsB) mutant in mouse intranasal infection model [92].  Furthermore, 
our data suggest that the clearance of the ΔmanC is likely initiated within few 
hours post infection (3.5 – 6.5 hr) and the development of the optical diagnostic 
tools facilitate observing these interesting phenomena.  
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4.2.8 Monitoring intracellular growth of K. pneumoniae   
 While often considered as an extracellular pathogen, we have recently 
demonstrated that K. pneumoniae is capable of replicating within cultured murine 
macrophages [99]. Therefore, we decided to investigate whether the intracellular 
proliferation of the bacteria can be monitored by bioluminescence. RAW264.7 
murine macrophages were infected with JSKP001 and ATCC 43816 using MOI 
of 10 and bacterial proliferation was monitored at 3, 4.5, 6, and 9 hr post infection 
using light measurement followed by lysing the cells and estimating bacterial 
numbers. Interestingly, even though the JSKP001 behaved like the parental 
strain where both bacteria were viable and replicating within the cells, over the 
short period of observation, JSKP001 bioluminescence was dropping 
exponentially (Figure 19). To determine if the loss of bioluminescence upon 
bacterial internalization is due to an issue with the rplU promoter, we have 
generated bioluminescent strains with other promoters including rpoD, ompC, 
EM7, and frr, and tested the ability of the bacteria to generate bioluminescence 
within host cells. J774A.1 murine macrophages were infected with MOI of 10 with 
the different strains, extracellular bacteria were killed using gentamicin treatment, 
and bioluminescence was monitored at 2, 3, 4, 5, 6, 9, and 12 hr post infection 
for intracellular bacteria. Only the strains with the rpoD and frr promoters were 
capable of generating a detectable bioluminescence at early time points followed 
by a time-dependent loss of bioluminescence similar to the JSKP001 strain 
(Figure 20). These outcomes suggest that the loss of bioluminescence for 
internalized K. pneumoniae is not due to a promoter issue but rather the bacteria 
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might be altering its metabolism after becoming intracellular as a way of adapting 
to that environment.  
Since we have shown that K. pneumoniae can survive in cultured 
macrophages, we next decided to determine if we could isolate intracellular 
bacteria during the respiratory disease. Mice were infected with 105.1 CFU using 
the JSKP001 strain and the amount of intracellular bacteria were estimated 43 hr 
post infection from lung homogenates. The estimation of the internalized bacteria 
was performed using two approaches: gentamicin protection assay and a 
filtration technique. Interestingly, a small percentage (<1%) of K. pneumoniae 
was internalized by host cells within the lungs and similar numbers were obtained 
from gentamicin protection and the filtration assays (Figure 21). Together, in 
addition to the previous observation about the capability of K. pneumoniae to 
proliferate within cultured macrophages, we demonstrated that a subpopulation 
of the bacteria become intracellular within mice lungs and it would be interesting 
to investigate the role of these internalized microbes in disease.  
 
4.3 DISCUSSION  
This work demonstrates that the bioluminescent K. pneumoniae strain we 
engineered can be utilized to monitor therapeutic efficacy in a surrogate animal 
infection model. BLI will minimize the number of animals needed in time course 
studies while at the same time allow for real-time monitoring of bacterial burden 
in live host. Using the JSKP001 strain, we were able to monitor bacterial 
dissemination to anatomical sites other than the initial site of infection (Figure 
 
   94 
 
12A), allowing the performance of studies directed toward characterizing 
secondary infections initiated following the pulmonary disease. The correlation 
observed between bioluminescence and bacterial numbers in culture media and 
in vivo makes the bioluminescent K. pneumoniae strain suitable for the 
performance of multiple studies including high throughput work while reducing 
the time, effort, and cost required for estimating viable microbes and eliminating 
the need for the invasive manipulation of host and bacteria. Interestingly, the high 
colonization of blood, liver, and kidneys is consistent with the ability of K. 
pneumoniae in causing septicemia, pyogenic liver abscess, and UTI in clinics 
[270-272].  
Bioluminescence enabled monitoring K. pneumoniae viability upon 
treating the bacteria with meropenem where both OD600 and light measurement 
gave similar outcomes. In addition, we provided an evidence that 
bioluminescence can be used as an alternative approach to estimate 
antimicrobial agents EC50 to the traditionally used OD600 measurement. Optical 
diagnostic imaging allowed for earlier prediction of disease outcomes, in which 
higher bacterial burdens in mice lungs correlated with quicker development of 
moribund disease (Figure 12C).  
In consistence with previous findings, we have demonstrated that deleting 
manC gene attenuated the ability of K. pneumoniae to cause the respiratory 
disease in our lung-specific disease model [92]. These outcomes is consistent 
we our previous finding demonstrating that removing K. pneumoniae capsule 
made the bacteria more susceptible to uptake by macrophages [99]. Thus, 
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resisting uptake by host immune cells play an important role in bacterial virulence 
in vivo during the respiratory disease but it is probably not the only factor. More 
importantly, we have demonstrated in current work by bioluminescence imaging 
(BLI) that the clearance of the capsule mutants is an early even that gets initiated 
within hours following infecting the animals.  
Using the bioluminescent strain, we identified the interesting phenomena 
that K. pneumoniae turn off bioluminescence when become intracellular 
suggesting that the bacteria might alter its metabolism to adapt to that 
environment. This intriguing observation led us to investigate how intracellular 
Klebsiella can get within host lungs and in consistence with the general notion 
about the extracellular property of K. pneumoniae we identified that >0.2% of the 
bacteria are detectable as being internalized into host cells in vivo. To the best of 
our knowledge, this is the first demonstration that a subpopulation of K. 
pneumoniae becomes intracellular during the respiratory disease. This 
subpopulation may represent K. pneumoniae being successfully cleared by 
professional phagocytes and/or K. pneumoniae which may resist killing after 
internalization as we have observed in our cell culture models (Figure 6). These 
findings support the classification of K. pneumoniae as an extracellular pathogen, 
and future studies will be required to determine whether the intercellular K. 
pneumoniae contribute to disease.  
Unlike other pathogens, capable of causing acute respiratory infection, 
animal infected with the same lethal dose of JSKP001 strain succumb to the 
infection at a broad MTTD range suggesting variable host susceptibility to K. 
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pneumoniae pulmonary disease (Figure 10A). Even though we have an excellent 
and reproducible lung-specific disease model [187], we observed ~1.3 log 
differences in bacterial lung colonization by 18 hr post infection (Figure 12B), 
which indicates a variation either in the bacteria as it try to evade killing by the 
host immune system or differences in host response to the invading pathogen. 
Future studies will need to be conducted to examine the contribution of host 
immune system in such phenomena. It is well known that neutrophil play an 
important role during K. pneumoniae respiratory disease [92, 102, 105-109, 113]. 
Thus, one way of testing if the variation observed in bacterial burdens at early 
time points is due differences in host immune response is by testing the 
recruitment of neutrophils at those time points by measuring blood cytokine 
levels involved in this process such as IL-8 and IL-17 [113, 273, 274].   
In the current study, we decided to use albino C57BL/6J mice as initial 
studies demonstrated that this strain is more resistant than the previous 
experience with the exquisitely sensitive BALB/c model to direct lung installation 
of ATCC 43816 [99, 275]. Furthermore, the main reason behind using the albino 
C57BL/6J in our studies was due to the availability of the genetic tools in that 
background for future investigation. The LD50 estimated for the JSKP001 strain in 
albino C57BL/6J mice is ~13.4 fold higher than the LD50 previously estimated for 
the parental strain ATCC 43816 in BALB/c further confirming the higher 
susceptibility of the BALB/c mice to the K. pneumoniae respiratory infection. In 
addition, blood, lung, liver, and spleen bacterial numbers for ATCC 43816 in 
moribund albino C57BL/6J mice were ~0.3 – 1.6 logs higher than the bacterial 
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loads observed previously in BALB/c mice for the same tissues [99]. These 
differences illustrate a significant variation in the susceptibility of the two mice 
strains to the pneumonic disease [99]. The differences in the susceptibility of the 
albino C57BL/6J and BALB/c mice to K. pneumoniae respiratory disease might 
be attributed to the genotypic differences of these mice strains [276, 277]. It is 
well known that C57BL/6 and BALB/c mice have different immune responses 
during health and disease [276-278] with C57BL/6 being mainly Th1 
proinflammatory type response and BALB/c being more of a Th2 type responder 
with more humoral protection [279-286]. For acute disease model it would be 
predicted that a mouse line favoring a Th1 response will more readily compact 
infection.  
In conclusion, we generated a bioluminescent version of K. pneumoniae 
ATCC 43816 which is frequently used strain in biomedical research. The 
bacterial fitness was not altered both in culture media and within the host. We 
demonstrated that bacterial viability upon antimicrobial treatment can be 
monitored both in vitro and in vivo model systems using light measurement. 
Bioluminescence can serve as an alternative way to traditionally used 
approaches for calculating antimicrobial agents EC50. Furthermore, the 
bioluminescent bacteria allowed for direct measurement of meropenem 
therapeutic efficacy against K. pneumoniae pulmonary disease with earlier 
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Figure 9. Growth curves of JSKP001 and ATCC 43816 strains. Overnight 
cultures of ATCC 43816 and JSKP001 were diluted 1000 fold in LB broth media 
and bacterial growth were monitored using SynergyTM H1 plate reader for 4 hr at 
37oC where OD600 and bioluminescence reads were taken every 10 min (A). (B) 
One thousand fold diluted overnight bacterial culture of JSKP001 strain were 
grown at 37oC for 3 hr where 100 µl aliquots were taken every 30 min for 
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Figure 10. Survival analysis and bacterial systemic dissemination. Albino 
C57BL/6J (8-10 weeks) were intratracheally infected with either ATCC 43816 
(104.95 CFU), or JSKP001 (104.91 CFU), and the survival curves from both animal 
groups (n = 5) were compared (A). Survival analysis is indicated on the figure. 
(B) Bacterial burdens of lungs, liver, spleen, kidneys, BAL, and blood estimated 
from moribund animals by plate count. (MTTD, median time to death; ns, not 
significant) 
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Figure 11. JSKP001 LD50 determination in albino C57BL/6J mice. Mice (n = 
5) were infected with 102 – 104.9 CFU of JSKP001 using IMIT, monitored for the 
development of the pneumonic disease over two week preiod, and eutanized 
when moribund. Animals median time to death (MTTD) is indicated on the figure. 
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Figure 12. In vivo tracking of bacterial proliferation. Albino C57BL/6J mice (n 
= 5) infected with JSKP001 (104.9 CFU) using IMIT and monitoed for the 
development of the respiratory disease using PhotonIMAGER Optima. (A) 
Representative mouse (M4) imaged for 1 min on dorsal (top panel) and ventral 
(bottom panel) positions. (B) Bioluminescence imaging of mice thoracic cavity 
(dorsal position) monitored twice daily. The dotted lines represent two standard 
deviation limit of detection (LOD) estimated from uninfected animals. (C) 
Correlation between bacterial burdens in mice thoracic cavity by BLI and time to 
euthanasia.  
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Figure 13. Correlation of bioluminescence and bacterial burdens in host 
tissues. Lung, liver, spleen, kidneys, BAL, and blood samples collected from 
moribund animals (n = 36) introduced with 103-105.2 bacteria using direct lung 
installation. (A – F) Ex vivo bioluminescence was measured using 
PhotonIMAGER Optima, and bacteria were enumerated from the processed 
samples. (G) Correlation between in life lungs bioluminescence before 
euthanasia and bacterial burdens from tissue homogenates. Ex vivo and in vivo 
correlations represented by the R2 values are indicated on the figure. In vivo 
bioluminescence from mice thoracic cavity were estimated before collecting the 
BAL while the ex vivo bioluminescence from the lung tissues were estimated 
following the BAL wash.  
 
 






Figure 14. Tracking bacterial viability upon MicroChem-Plus treatment using bioluminescence. JSKP001 
viability upon treating the microbes with different concentrations of MicroChem-Plus disinfectant tracked by 
bioluminescence (A) and by bacterial numbers (B) estimated at 11 min post treatment. (C) Correlation between 
bacterial numbers and bioluminescence at 11 min from wells with viable bacteria.  
  
 





Figure 15. Monitoring the impact of meropenem treatment on bacterial 
growth using bioluminescence. Exponentially growing JSKP001 bacteria were 
diluted (105.9 CFU), treated with serially diluted meropenem, and bacterial growth 
was monitored by OD600 (A) and bioluminescence (B) at 5 m intervals. 
Meropenem EC50 estimated by OD600 (C) and bioluminescence (D) at 8 hr post-
treatment.    
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Figure 16. In vivo monitoring of meropenem efficacy against K. 
pneumoniae respiratory infection in mice. Lethally infected (104.9 CFU) albino 
C57BL/6J mice 8-10 weeks (n = 3) were treated with subcutaneous (s.c.) 
injection q12h of 400, 200, 96 mg/kg/day meropenem, or PBS vehicle. (A) 
Survival curves of mice receiving the different therapeutic treatments. Survival 
analysis and median time to death (MTTD) is indicated on the figure. (B – E) 
Animals monitored for the development of the respiratory disease twice a day by 
tracking bioluminescence emitted from the thoracic cavity (dorsal image). (F- I) 
Mice heart rates estimated twice daily using MouseOx system. The dotted lines 
and the gray shades represent three standard deviation from background mean. 










Figure 17. Noninvasive monitoring of JSKP001ΔmanC fitness in mice. Albino C57BL/6J mice (n = 5) infected 
with JSKP001 (104.1 CFU) or JSKP001ΔmanC (108 CFU) using IMIT and monitored for development of the 
respiratory disease for two weeks. (A) Survival curves of animals infected with the manC mutant and wild type 
parental strain. (B) Bacterial burdens of capsule mutant in mice thoracic cavity monitored by optical diagnostic 
imaging. (C) Bacterial burdens in tissues collected following euthanasia upon moribund disease or 14 days post 
infection. The closed circles (●) represent animals that survived the respiratory disease. Dotted lines represent two 









Figure 18. Tracking the clearance of the capsule mutant using bioluminescence imaging. Albino female 
C57BL/6J mice (n = 4) were infected with 108 CFU with JSKP001ΔmanC using IMIT. (A) Bacterial proliferation 
within animals’ lungs tracked using BIOSPACE LAB PhotonIMAGER Optima system at 0.5, 3.5, and 6.5 hr post 
infection. (B) Bacterial burdens enumerated from mice lungs 6.5 hr post infection. (C) Correlation between thoracic 
cavity bioluminescence in life and bacterial burden in mice lungs following euthanasia. 
  
 




Figure 19. Monitoring bacterial replication within cultured macrophages. 
Gentamicin protection assay was performed where RAW264.7 murine cells were 
infected with JSKP001 or ATCC 43816 using MOI of 10 and bacterial numbers 
were estimated at 3, 4.5, 6, and 9 hr post infection. Bioluminescence was 
monitored for the JSKP001 strain at the same time points using SynergyTM HT 












Figure 20. Tracking K. pneumoniae proliferation within cultured 
macrophages using different promoter systems. J774A.1 cells were infected 
with MOI of 10 using the strains indicated in the figure, extracellular bacteria 
were killed using gentamicin treatment at 1 hr, and intracellular bacteria were 
monitored at 2, 3, 4, 5, 6, 9, and 12 hr post infection by measuring 














Figure 21. Estimating bacterial internalization into host cells within mice 
lung. Albino C57BL/6J mice were intratracheally infected with JSKP001 (105.1 
CFU). Animals were euthanized 43 hr post infection, lungs were collected, 
dissociated into single cell suspension using collagenase treatment, and total 
bacterial loads were estimated following treating the tissue homogenates with 
Triton X-100. Intracellular bacteria were estimated by running 106 cells through 5 
micron filter to wash off extracellular microbes followed by lysing the cells using 
Triton X-100 for intracellular bacterial estimation. Internalized bacteria were also 
estimated from 106 cells using gentamicin protection assay. Percent intracellular 
represent the percentage of the internalized K. pneumoniae to the total bacterial 









DISCUSSION AND FUTURE DIRECTIONS 
 
 Collectively, we have provided the first draft of the K. pneumoniae ATCC 
43816 sequence and compared the genome of that strain to two previously fully 
sequenced K. pneumoniae strains, and identified shared known and potential 
virulence determinants between ATCC 43816 and NTUH-K2044, disease 
causing strains, that are absent from the avirulent MGH 78578 strain. We studied 
the uptake of the three K. pneumoniae strains by cultured macrophages, 
investigated the involvement of the capsular polysaccharide (CPS) in this 
process, and provided the first evidence that K. pneumoniae strains are capable 
of intracellular proliferation. We established a unique pulmonary infection model 
where we can specifically deliver the microbes into mice lungs allowing us to 
study colonization of the lower respiratory tract (LRT). Using that model system 
we demonstrated that both ATCC 43816, NTUH-K2044 were highly virulent to 
BALB/c mice while MGH 78578 was relatively avirulent requiring a very high 
dose in order to cause the disease. We used the recently constructed 
bioluminescent JSKP001 strain to conduct multiple investigations including 
noninvasive monitoring of bacterial proliferation in broth media and in vivo, 
tracking of microbial viability upon bactericidal agents’ treatment, estimating 
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antimicrobial drugs EC50, monitoring the efficacy of therapeutic in vivo with earlier 
prediction of disease outcomes, and direct monitoring of the fitness of capsule 
mutant. 
 
5.1 Identifying virulence factors required by K. pneumoniae to establish the 
respiratory disease using Tn-seq 
Even though K. pneumoniae is an important pathogen capable of causing 
acute diseases in human, only few virulence determinants were identified to be 
required for the respiratory disease caused by these bacteria. Conversely, 
pathogens that cause similar infection such as Streptococcus pneumoniae, 
Staphylococcus aureus, Legionella pneumophila, Haemophilus influenza, and 
Yersinia pestis encode for an arsenal of virulence determinants that play a role in 
the disease induction [287-293]. In the case of Legionella pneumophila, it is 
thought is possesses over 300 proteins secreted by a type 4 secretion system to 
facilitate its intracellular lifestyle [287]. Therefore, we propose that there are other 
unidentified virulence factors required by K. pneumoniae to cause pulmonary 
disease within a host and the identification of these factors would help the 
discovery of new therapeutic targets for this critical pathogen.  
Tn-seq is one of the most recent methods utilized for the identification of 
virulence factors required by a microbial pathogen [294-296]. It combines 
transposon mutagenesis together with massive parallel sequencing (MPS) to 
identify fitness factors required by a microorganism to survive under a set of 
growth conditions or selective pressures. We decided to employ Tn-seq for the 
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purpose of identifying virulence factors that contribute into K. pneumoniae 
respiratory disease using the models developed by our group. A Tn-seq library 
was generated in the bioluminescent JSKP001 strain to enable monitoring the 
specific inoculation and proliferation of the mutants in host lungs. A library of 
20,000 transposon mutants was generated representing approximately four-fold 
coverage of the K. pneumoniae genome size (~5.4 MB).  
 Five mice were infected with 104.8 CFU by IMIT and monitored for the 
development of the respiratory disease by optical diagnostic imaging and 
euthanized upon reaching thoracic cavity bioluminescence of 108 ph/s (Figure 
22B), representing late stage disease. Median time to endpoint criteria was 
estimated to be 1.8 days (Figure 22A), which is consistent with previous data 
with the exception that we did not allow the animals to reach bradycardia 
moribund endpoint previously established. Bacterial burdens in mice lungs were 
~109 CFU (Figure 22C), also consistent with previous outcomes (Figure 10B). 
The chromosomal DNA was extracted from the inoculum (input pool) and from 
the transposon libraries collected from lungs homogenates (output pool) to be 
used in subsequent analysis. This is an ongoing that is being conducted in 
collaboration with Dr. Deborah Yoder-Himes. 
 
 








Figure 22. Noninvasive monitoring of JSKP001 Tn-seq library in lung-specific disease model. Albino 
C57BL/6J mice (n = 5) infected with 104.8 CFU of JSKP001 transposon library using IMIT and bacterial colonization 
of host lungs were monitored using BIOSPACE LAB PhotonIMAGER Optima system. (A) Survival curve with 
estimated median time to endpoint criteria of 1.8 days. (B) Animals monitored for lung colonization by the 
transposon library using bioluminescence imaging and euthanized upon meeting in vivo lung bioluminescence of 
108 ph/s. Upper dotted line represent the threshold for euthanasia and the lower one indicate 2 standard deviation 
limit of detection (LOD) estimated from uninfected animals. (C) Bacterial burdens for the indicated tissues collected 
following mice euthanasia.  
  
 
  117 
 
 
5.2 The role of T6SS for K. pneumoniae in disease 
As the Tn-seq study is an ongoing work, we decided to investigate the role 
of other virulence systems that might play a role during K. pneumoniae 
respiratory disease. Type six secretion systems (T6SS) are among a recently 
identified secretion systems of Gram-negative bacteria that is functionally and 
evolutionary uniquely similar to T4 bacteriophage injectisome [297]. T6SSs play 
a role in virulence in multiple important pathogens as well as in bacterial 
competition [296, 298-302]. K. pneumoniae strains encode for 2 – 3 clusters of 
T6SSs [303] and for ATCC 43816 K. pneumoniae strain it encodes two clusters 
of those secretion systems [99, 304]. Previous studies have suggested a 
potential role for T6SS cluster 1 in K. pneumoniae intranasal murine model of 
respiratory disease, in which a mutant was less efficient in dissemination to 
spleen [92]. That mutant was identified in signature tagged mutagenesis but it 
was not further characterized. Due to the importance for T6SS for the virulence 
of other pathogens, we predicted that it might play a role in K. pneumoniae 
respiratory disease. Having developed the capability to manipulate K. 
pneumoniae genome, we decided to create T6SS mutants and investigate their 
importance for the pulmonary disease using our lung-specific disease model.  
T6SS mutants were created through the deletion of the vgrG genes which 
are required for a functional secretion system [297]. Single vgrG knockouts were 
made in each T6SS cluster of the JSKP001 strain as well as in both clusters 
creating the strains JSKP001ΔvgrG1, JSKP001ΔvgrG2, and JSKP001ΔvgrG1/2. 
The fitness of the different vgrG mutants were compared to their parental strain 
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in albino C57BL/6J mice where the different strains were inoculated into animals’ 
lungs with 104.8 – 104.9 CFU using IMIT. The vgrG mutants were as virulent as 
their parental strain in the single strain infection study performed with a MTTD 
ranging from 2.4 – 3.8 days (Figure 23A). In addition, bacterial loads in blood, 
BAL, lungs, liver, kidneys, and spleen were similar between animals infected with 
the vgrG mutants and the wild type strain (Figure 23B).  
  
 






Figure 23. In vivo fitness of K. pneumoniae T6SS mutants. Albino C57BL/6J mice (n = 5) infected with 104.8 – 
104.9 bacteria of the vgrG mutants indicated the figure using IMIT. (A) Survival curves of the mice inoculated with 
the different vgrG mutants in comparison to the parental JSKP001 strain. Median time to death (MTTD) is indicated 
on the figure. (B) Bacterial burdens in tissues collected from moribund mice following euthanasia. 
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Previous work demonstrated that competition studies is a higher resolution 
method for identifying subtle phenotypes that were indistinguishable by single 
strain infection [296], and thus we decided to employ this approach for testing the 
potential contribution of T6SS in K. pneumoniae respiratory disease. Each of the 
vgrG bioluminescent mutants was inoculated into albino C57BL/6J mice lungs in 
1:1 ratio with the non-luminescent ATCC 43816 strain (104.9 – 105.4 CFU). The 
animals were monitored for the development of the respiratory disease and 
euthanized upon meeting a heart rate of 500 bpm or below. Following 
euthanasia, blood, lungs, liver, and spleen were collected and processed for 
bacterial enumeration. The luminescent bacteria were distinguished from the 
non-luminescent wild type strain using optical diagnostic tools allowing us to 
calculate output ratios of bacteria on LB plates and estimate in vivo bacterial 
burdens of the JSKP001 strains.  
Interestingly, most of the animals infected with the vgrG1 knockout strain 
had reduced in vivo colonization of the lungs (Figure 24A), distinguished from the 
wild type ATCC 43816 strain by luminescence, and an alleviated competition 
indexes in comparison to ATCC 43816 in all tested tissues (Figure 24B. To 
confirm that the potential reduction of vgrG1 mutant fitness was not due to early 
euthanasia of the animals infected with that mutant we estimated the total 
bacterial burdens in the collected tissues. We found no pronounced difference in 
total bacterial numbers from all collected tissues suggesting that all animals were 
euthanized with the same level of disease (Figure 24C). Conversely, we 
observed no reduced fitness of the vgrG double knockout strain which was 
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expected to at least demonstrate similar phenotype to the vgrG1 mutant. These 
outcomes suggest that T6SS cluster 1 might be required for K. pneumoniae 
respiratory disease but due to the inconsistent observations more future 









Figure 24. Fitness of the vgrG mutants in competition to the wild type strain. Albino C57BL/6J mice (n = 3) 
were co-infected with the ATCC 43816 with one of the vgrG mutants indicated at 1:1 ratio and animals were 
euthanized upon meeting a heart rate of 500 bpm or below. (A) In vivo lung bacterial burdens of the luminescent 
JSKP001 strains estimated before euthanasia. (B) Competitive indexes of the JSKP001 strains in comparison to 
the ATCC 43816 strain in blood, lung, liver, and spleen. (C) Total bacterial burdens of the non-luminescent ATCC 
43816 and the luminescent JSKP001 strains in blood, lung, liver, and spleen. 
  
 




 We have demonstrated a potential role for T6SS cluster 1 for K. 
pneumoniae respiratory infection using competition infection model which will be 
followed by future investigations to confirm the proposed hypothesis. In addition 
to the importance of T6SSs in disease for other pathogens, these secretion 
systems play a role in bacterial competition (also known as bacterial dueling) 
[296, 298-302, 305].  Using the bioluminescent K. pneumoniae, we have 
observed frequent colonization of mice gut following the intratracheal 
administration of the bacteria. It is well known that mammalian gut is heavily 
colonized by many normal flora and therefore, K. pneumoniae might use its 
T6SSs to compete with other microbes in order to survive in that environment. 
The main mode of transmission of Klebsiella is fecal-oral route in which the 
bacteria spread in health care settings through the contaminated hands of 
patients, and health care providers due to unhygienic practices eventually 
leading to contamination of medical equipment [23, 223]. Respiratory ventilators 
are one of the medical devices that become contaminated by the bacteria and K. 
pneumoniae is known to be a causative agent for VAP [39].  
Thus, we would like to propose a model where K. pneumoniae spread 
from lungs of patients with respiratory disease into the gut where the bacteria 
uses its T6SS to compete with other microbes to thrive in that niche in addition to 
the possibility of acquiring antibiotic resistance genes followed by bacterial 
shedding in feces and without proper hygienic practices, medical devices 
become contaminated with K. pneumoniae leading to spread of the pulmonary 
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disease to other hospitalized individuals (Figure 25). The proposed model is in 
consistence with the finding that the length of hospitalization is associated with 
higher possibility of acquiring K. pneumoniae infection [21].   
One possible method of testing the proposed hypothesis is through 
infecting mice with bioluminescent wild type and the T6SS mutants using IMIT, 
monitoring development of the respiratory disease and bacterial dissemination to 
the gut using BLI, euthanizing animals at moribund endpoint, collecting their gut 
tissues, and estimating the amount of gut colonization by the T6SS mutants in 
comparison to the wild type bioluminescent strain using optical diagnostic 
imaging. If K. pneumoniae uses its T6SS to compete with other gut flora, then we 
would expect that deleting this secretion system will impact the ability of the 
bacteria to survive in the gut and if the proposed model was accurate then 
targeting T6SS would break the cycle of K. pneumoniae transmission. 
 
 




Figure 25. Proposed model of the indirect contribution of T6SS in K. 
pneumoniae nosocomial respiratory disease. K. pneumoniae disseminate 
from patient with pulmonary infection into the gut where the bacteria uses its 
T6SS to compete with other commensal microbes. The bacteria get shed into 
feces and without proper hands cleansing techniques, medical equipment 
become contaminated with K. pneumoniae. Contamination of ventilators or 
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5.3 The presentation of pulmonary disease using IMIT  
 IMIT was developed and refined in K. pneumoniae before its application 
on in Burkholderia pseudomallei, the other respiratory pathogen that we study in 
our laboratory. In B. pseudomallei IMIT lead to the development of pulmonary 
infection in mice that resemble the human presentation of the disease more 
closely than intranasal infection model and such observation was made possible 
due to the development of a bioluminescent derivative of the bacteria in 
combination with in vivo imaging capability [306]. We do not know if the same 
phenomena take place in K. pneumoniae since we have started using IMIT since 
we started working with this pathogen in our laboratory. What we know for sure 
that using IMIT we can deliver >98% of an inoculum into animals’ lungs [187] and 
using this technique, we improved the specific delivery of K. pneumoniae into 
mice lungs as demonstrated by reduction in LD50 for the ATCC 438161 strain 
than what have been reported previously for BALB/c mice infected with intranasal 
route [99].  
Introducing K. pneumoniae into mice lungs using IMIT somewhat 
resemble how an individual would acquire ventilator associated pneumoniae 
(VAP) in the hospital. Therefore, we speculate that IMIT recapitulate human 
disease more than other infection models such as the intranasal route frequently 
used in K. pneumoniae animal studies. The advantage of having bioluminescent 
K. pneumoniae strain that was generated in ATCC 43816 background, strain 
frequently used in biomedical research, will facilitate such comparison as it did 
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with B. pseudomallei [306]. IMIT can also facilitate studies other than disease 
presentation upon infecting animals using different routes of infections.  
This method of bacterial delivery would allow for examining host response 
to K. pneumoniae respiratory infection following activating host immune system 
using direct installation of an immune stimulating agent into mice lungs using 
IMIT. Using the same principle, IMIT would facilitate vaccine studies where the 
vaccine can be introduced directly into animals’ lungs followed by bacterial 
administration. Since we can instill the bacteria directly into host lungs, we can 
use IMIT to identify factors required by K. pneumoniae to disseminate from the 
lungs and colonize other tissues. Such factors would be identified from the Tn-
seq analysis study that we have performed where dissemination defective 
mutants will be present in the lungs and missing from other anatomical sites. The 
confirmation of such defect will be achieved by deleting the predicted factors 
using targeted mutagenesis and then introduce the bacteria into the host lungs 
using IMIT and follow bacterial dissemination using bioluminescence imaging 
(BLI).   
 
5.4 The importance of intracellular life style for K. pneumoniae 
pathogenesis 
 K. pneumoniae is considered as an extracellular pathogen but our data 
have demonstrated that this concept is not entirely true. In addition to the 
demonstration that K. pneumoniae strains are capable of replication within 
cultured macrophages [99], we have also established that a part of the bacterial 
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inoculum become internalized within host cells in vivo following introducing the 
microbes into mice lungs. This phenomena raises the question whether this 
intracellular phenotype is something promoted by the bacteria as a way to evade 
host immune response or by the host as mechanism of protection against the 
invading pathogen. The fact that deleting the CPS increased internalization of the 
bacteria into host cells [99], suggest that K. pneumoniae resist uptake by host 
cells using that structure but that does not eliminate the possibility that the 
microbes might be promoting their own uptake since that the intact parental 
strains get internalized and even replicate within host cells.  
The intracellular subpopulation of K. pneumoniae might get protected from 
host immune responses and from antimicrobial agents introduced into a host 
during therapy. Following the eradication of the extracellular population, the 
internalized bacteria might then serve as a reservoir to reestablish the 
pneumonic disease in the host. To test this hypothesis we can infect mice with 
the bioluminescent K. pneumoniae, allow the disease to develop for a short 
period of time, treat the animals with antimicrobial agents that work against 
extracellular microbes only, monitor the animals health status and BLI over a 
prolonged time points to track in they are going to undergo recurrent infection, 
and finally euthanize mice at different time points to test for the presence of 
intracellular bacteria.   
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5.5 Future implications for the bioluminescent K. pneumoniae 
 In addition to the previously discussed implication for the bioluminescent 
K. pneumoniae in distinguishing the respiratory disease presentation following 
inoculating the microbes through different routes, the JSKP001 will also facilitate 
other investigations. The bioluminescent strain will facilitate the performance of 
high throughput studies such as in vitro estimation of drugs EC50 and in vivo 
therapeutic efficacy such as the study that we conducted for testing meropenem 
direct effectiveness against K. pneumoniae respiratory disease. The same 
concept can be applied for testing the efficacy of other antimicrobial agents or 
assessing the efficacy of combinational therapy noninvasively. 
In combination with IMIT, the bioluminescent K. pneumoniae will allow for 
the performance of multiple studies to improve our understating host response to 
the pulmonary disease. We have demonstrate that even with the very successful 
lung-specific bacterial delivery approach developed by our group [187], K. 
pneumoniae undergo ~1.3 log variation in bacterial load by the 18 hr post 
infection. This variation continue throughout the time course of the experiment in 
which animals that had higher colonization at the 18 hr time point developed 
moribund disease more rapidly than those with lower bioluminescence signal. 
One explanation for such phenomena is that the host response to K. pneumoniae 
respiratory disease is variable in which some animals develop quicker response 
to the respiratory disease. We hypothesize that mice with less bacterial burdens 
early at disease might demonstrate earlier and higher levels of neutrophil 
recruitment known to be critical during the pneumonic disease [273].   
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Such hypothesis can be examined by infecting animals with the 
bioluminescent strain, monitor the development of the pneumonic disease using 
optical diagnostic imaging, and perform cytokine analysis profiles such as 
interleukin (IL)-8 and IL-17 at different time points during the course of the 
disease. We expect to detect differences in mice immune response in which 
animals with lower bacterial numbers early in disease might have higher 
proinflammatory cytokines levels indicative of early clearance which eventually 
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